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SUMMARY
In human health, nickel (Ni) is mainly known as a toxic metal, especially 
as an allergenic and carcinogenic agent. There is, however, experimental 
animal evidence of its role as an essential element (Sunderman, 1984).
Nickel toxicity has been widely investigated in relation to occupational 
exposure. Health hazards for workers exposed to fumes and dusts of this 
element and its compounds include dermatitis, increased incidence of 
nasal and lung cancer, chronic diseases of the respiratory tract and 
chromosomal aberrations (Sunderman, 1984; IARC, 1986; Niebor et al., 
1988; IPCS, 1991).
The risk of adverse effects due to Ni toxicity is not confined to the work­
place. Because of the widespread use of Ni in modern societies, an 
increasing number of the general population report allergic dermatitis 
induced by contact with jewellery, coins and utensils, containing Ni 
(Edman and Moeller, 1982; McDonagh et al., 1992).
Toxicity may also result from inadvertent exposure to Ni due to medical 
treatments, such as haemodialysis, intravenous administration of 
contaminated pharmaceuticals and blood products, and implant of medical 
devices, such as orthopaedic and orthodontic prosthesis, made of alloys 
containing Ni (Webster et al., 1980; Olerud et al., 1984; Leach and
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Sunderman, 1985; Fell and Maharaj, 1986; Leach and Sunderman, 1987; 
Gammelgaard and Sandberg, 1989; Landwehr and Van Ketel, 1983; 
Romaguera and Grimalt, 1985; Vrignaud et al., 1991; Oleffe and Wilmet, 
1980; Fine and Karwande, 1990; Wilson and Gould, 1989; Espana et al., 
1989; Romaguera et al., 1989; Dunlap et al., 1989; Zoccola et al., 1990; 
Taylor and Morton, 1991; Burden and Eedy, 1991; Guyuron and Lasa, 
1992; Trombelli et al., 1992;). Besides the risk of acute adverse reactions 
in hypersensitive subjects, the effect of prolonged exposure to low doses 
of Ni may be of concern. Several reports indicate increased 
concentrations of Ni in serum of patients undergoing regular 
haemodialysis (Drazniowsky et al., 1985; Wills et al., 1985; Hopfer et al., 
1985; Hopfer et al., 1989; Nixon et al, 1989). Patients with impaired renal 
function may be at higher risk of Ni retention and accumulation in tissues.
The assessment of risks arising from exposure to low doses of Ni is 
hampered by the difficulties of Ni analysis at low concentrations and the 
resultant uncertainty as to the 'true' reference values for a healthy 
population. Since 1985, the concentrations reported for Ni in serum of 
unexposed subjects decreased from 1.0 to 0.14 pg/l, (Drazniowsky et al., 
1985; Nixon et al, 1989). This suggests that the actual extent of iatrogenic 
exposure to Ni needs re-evaluation, using more accurate methods.
In this work, I have measured the concentration of Ni in human albumin
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solutions used for intravenous administration, which have been produced 
by different manufacturers, at different times. Additional results for the 
concentrations of other metals, at various stages of the production 
process, were also obtained using multielement semiquantitative scanning 
by inductively coupled plasma-mass spectrometry (ICP-MS) (Chapter 2).
In the last ten years, increasing efforts have been made to limit the 
contamination of dialysis fluids with metals, present in water, salts and 
haemodialysis equipment. This was intended to eliminate aluminium 
toxicity and may have incidentally also reduced Ni contamination. Results 
for Ni concentrations in the serum of haemodialysed patients are limited 
and sometimes contradictory, compared to the vast literature on serum 
aluminium concentrations. The assessment of Ni concentrations has 
proven more difficult, due to problem of pre-analytical contamination and 
the lower concentrations present. In Chapter 2 I report an investigation of 
the serum Ni concentrations in a group of patients undergoing regular 
haemodialysis and the effect a single dialysis treatment has on serum Ni 
concentrations in the same subjects.
The understanding of the toxicology of Ni at low doses will benefit from 
improved knowledge of Ni biochemistry and metabolic pathways. Several 
studies have been carried out to investigate the metabolism of Ni in man 
(Nodiya, 1972; Cronin et al., 1980; Solomons et al., 1982; Gawkrodger et
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al., 1986; Sunderman et al., 1989) but only two report data on faecal 
excretion (Nodiya, 1972; Sunderman et al., 1989). There was a large 
inter-individual variability in the estimates of Ni absorption and excretion. 
In all the experiments, volunteers ingested Ni, as the naturally occurring 
mixture of five isotopes, and results could be affected by the contribution 
of Ni from diet and contamination of samples prior to analysis.
Nickel metabolism has been studied in rats and rabbits using 
radioisotopes (63Ni, 57Ni) (Onkelinx et al., 1973; Nielsen et al., 1993) but 
limitations of radiation dosage prevent the application of this technique in 
man.
The recent development of ICP-MS, which can provide information on 
the isotopic composition of an element using simplified procedures, offers 
the opportunity to apply stable isotopes for the study of mineral 
metabolism in humans on a larger scale.
Different separation procedures were used to remove the mass 
interferences affecting the determination of the minor Ni isotopes in 
human albumin solutions, blood, erythrocytes, urine, faeces and tissues. A 
method was developed, that allowed the determination of three out of five 
Ni isotopes, one of which was used for isotopic dilution (Chapter 3).
Nickel metabolism was investigated in four volunteers, who ingested a 
single dose of 62Ni as a tracer. Nickel absorption, distribution and
6
excretion were determined by analysing plasma, urine and faeces, 
collected at various time intervals for up to five days (Chapter 4).
The role of Ni in the human environment and the present knowledge on 
its biochemistry, metabolism, health effects and analytical methods of 
determination are summarised in Chapter 1.
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CHAPTER 1
NICKEL IN THE HUMAN ENVIRONMENT
1.1 INTRODUCTION
Human exposure to Ni, its metabolism, toxicology and analytical 
biochemistry have been extensively reviewed (Sunderman, 1984; Sigel 
and Sigel, 1988; IPCS, 1991; Sunderman and Oskarsson, 1991). The aim 
of this chapter is to provide a concise summary of the present knowledge 
on these various aspects of the interaction of Ni with the human 
environment, with particular attention to the most recent findings.
1.2 PROPERTIES, SOURCES, PRODUCTION AND USES OF NICKEL
Nickel, atomic number 28, is the 24th element in order of abundance in 
the earth's crust and is found almost everywhere in the biosphere. Its 
average atomic mass is 58.71 and comprises a mixture of five natural 
isotopes with atomic masses 58, 60, 61, 62 and 64 and relative 
abundance: 68.077%, 26.223%, 1.140%, 3.634% and 0.926%,
respectively (Holden, 1993). Its high melting point (1453°C), excellent
8
resistance to corrosion and ability to form many alloys make Ni a very 
useful metal for a variety of applications.
World production of Ni ranges from 700,000 to 900,000 tonnes/year, 
mainly extracted from pentlandite and laterites deposits in Canada (26%), 
the USSR (19%) and New Caledonia (12%) (Sigel and Sigel, 1988; IPCS, 
1991). Pure Ni is obtained from the mined ore by pyro- and hydro- 
metallurgical refining processes (IPCS, 1991). Most of the Ni is required 
for the production of stainless steel and other alloys with high corrosion 
and temperature resistance.
Nickel alloys and Ni plating are used in vehicles, processing machinery, 
armaments, tools, electrical equipment, household appliances, cooking 
utensils, jewellery, coinage, medical devices, like surgical and dental 
prostheses, computer components and Ni-Cd storage batteries. Pigments 
for paints, glass and ceramics are based on Ni compounds. Nickel 
catalysts are used for organic syntheses; petroleum refining; 
hydrogenation of edible fats, oils and other organic compounds (Sigel and 
Sigel, 1988; IPCS, 1991).
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1.3 ENVIRONMENTAL LEVELS AND HUMAN EXPOSURE
Atmospheric Ni concentrations in remote areas range from 
<0.1 to 0.8 ng/nA Levels from about 5 to 35 ng/m^ are found in rural and 
urban air due to the combustion of fossil fuel such as diesel oil, coal and 
oil for heat or power generation; the incineration of waste and sewage 
sludge and emissions from oxidative catalytic converters for automobile 
exhaust gases (Sunderman, 1986; Boyle and Robinson, 1988). Higher 
levels are found in larger cities and industrialised areas. Nickel 
concentrations as high as 3.3 pg/m^ can occur near Ni smelters (Boyle 
and Robinson, 1988).
Nickel content in natural water ranges between 0.1 and 0.7 pg/L in sea 
water, depending on depth, and between 2 and 20 pg/L in fresh water, 
owing to dissolution of rocks and soil, atmospheric fallout, industrial 
processes and waste disposal. Drinking water generally contains less than 
10 pg/L Ni, but much higher Ni concentrations may be found in areas 
where Ni is mined. Leakage from the plumbing fittings can increase Ni 
levels in tap water up to 500 pg/L (Grandjean, 1984). A directive of the 
Council of the European Communities establishes the limit of 50 pg/L of Ni 
for water for human consumption (Council of the European Economic 
Communities. Directive n. 80/778, 15/7/1980).
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Nickel can accumulate in plants grown on sewage sludge-treated soils 
and in vegetation close to Ni-emitting sources. In wildlife, Ni is found in 
many organs and tissues due to dietary uptake by herbivorous animals 
and their carnivorous predators. However, there is little or no evidence of 
biomagnification in the food chain (IPCS, 1991).
Nickel concentration in food are usually below 0.5 mg/Kg fresh weight 
(Sigel and Sigel, 1988; IPCS, 1991). The highest levels were found in 
cocoa (10 mg/Kg) and nuts (5 mg/Kg). Also soya products, dried legumes, 
wheat bran, oatmeal, licorice, tea leaves and sunflower seeds were found 
to contain Ni concentration > 1 mg/Kg. Vegetables and grains are richer in 
Ni than animal muscle. Bovine meat contains from 1 to 13 pg/Kg of Ni and 
bovine liver from 70 to 180 pg/Kg. Shellfish and Crustacea may have 
higher content of Ni compared with other fish.
Daily dietary intake of man varies according to the composition of the 
diet. In early studies the average Ni intake was estimated to be 
168 pg/day for American adults (Myron et al., 1978), 290 pg in the USSR 
(Nodiya, 1972) and between 200 and 300 pg/day for people living in 
Western countries (Clemente et al., 1980). In more recent investigations, 
the Ni daily dietary intake per person was estimated as 150 pg/day in 
Denmark (Nielsen and Flyvholm, 1984), 150-170 pg/day in Great Britain 
(Smart and Sherlock, 1987), 90-100 pg/day in Sweden (Becker and
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Kumpulainen, 1991) and between 142 and 222 pg/day in Germany (Anke 
et al, 1991). However, Nielsen and Flyvholm (1984) stressed that Ni 
intake could reach a level of 900 pg/day with the introduction of certain 
items such as soya products, dark chocolate or oatmeal in the average 
diet. Vegetarians may ingest three or four times the average amount of Ni, 
especially if nuts and chocolate are included in their diet. Regular 
consumption of canned food may also increase the dietary intake of Ni.
Nickel content of food may be augmented during food processing, 
particularly in operations involving stainless steel equipment (which may 
release Ni), the milling of the flour and the hydrogenation of fats and oils 
using Ni catalysts (IPCS, 1991).
Although the addition of Ni to alloys reduces corrosion, Ni can be 
released from kitchen utensils, including stainless steel ones. The 
contribution of these sources, including leaching from water pipes and 
fittings, to the average daily intake of Ni can occasionally reach 1 mg/day 
(Grandjean, 1984). In a more recent study, the average contribution from 
metal cooking ware was estimated as 100 pg/day (Smart and Sherlock,
1987).
Occupational exposure to Ni occurs during Ni production and refining; 
welding, plating and grinding; in steel plants, foundries and other metal 
industries (Sunderman, 1984; Sigel and Sigel, 1988; IPCS, 1991). In most
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countries, limits of less 1 mg/m^ have been established for the 
concentration of atmospheric Ni at work-place (Sunderman and 
Oskarsson, 1991).
1.4 NICKEL METABOLISM IN MAN
Due to environmental and occupational exposure, Ni enters the human 
organism and it is found in all body fluids and tissues. The reported Ni 
content in human biological samples has decreased over the years, owing 
to improvement of analytical methods and techniques of sampling and 
storage. However, because of the high risk of contamination and the low 
levels to be determined, rather few reliable data are available. Some of 
the most recent available estimates of Ni content in human body fluids 
and tissues are given in Tables 1.1 and 1.2.
The total content of Ni in the human body has been estimated as 0.5 
mg, assuming a mean concentration in tissue of 7 pg/Kg (Bennett, 1985).
Ni uptake occurs mainly through inhalation and ingestion. Penetration 
through the skin is negligible, but may have important health effects, 
causing sensitisation and contact dermatitis. The degree of absorption 
and clearance is influenced by the physico-chemical properties, 
especially solubility, of the Ni compounds. For the general population, Ni
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Table 1.1 Selection of values (mean ± s.d. or range) recently reported
for Ni content of human body fluids.
Matrix Ni, pg/L N. Reference
Serum 0.46± 0.26 39 Sunderman et al., 1984
0.28± 0.24 30 Hopfer et al., 1985
0.14±0.09 38 Nixon et al., 1989
Urine 2.0± 1.5 34 Sunderman et al., 1986
0.9 ±0.11 878 Minoia et al., 1990
Whole blood 1.26± 0.33 30 Sunderman et al., 1984
0.34± 0.28 30 Hopfer et al., 1985
Bile 2.3 ±0.8 5 Rezuke et al., 1987
Saliva 1.9±1.0 38 Catalanatto et al., 1977
0 .11± 0.08 12 Hopfer et al., 1985
Sweat3 4.0(1.0-7.6) 10 Pedersen et al., 1985
Milk3 (<4.4 -29.6) 16 Mignorance and Lachica, 1985
3 median (range)
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Table 1.2 Selection of values (mean ± s.d. or range) recently reported
for Ni content of human tissues and faeces.
Tissue N Ni, ng/g 
Wet Weight
Ni, ng/g 
Dry Weight
Reference
Lung 15 180±0.105 Seeman et al., 1985
9 18 ± 12 173±0.094 Rezuke et al., 1987
170±0.110 Kollmeier et al., 1990
30 20.2-40.03 107.2-195.43 Raithel et al., 1988
Hilum (left/right) 30 76.7/95.6b 387.3/468.3b
Thyroid 8 20±10 141±83 Rezuke et al., 1987
Adrenal 10 26±15 132±84 Rezuke et al., 1987
Kidney 18 34±22 Seeman et al, 1985
10 9±6 62±43 Rezuke et al., 1987
Heart 9 8±5 54±40 Rezuke et al., 1987
Liver 23 18±21 Seeman et al, 1985
10 10± 7 50±31 Rezuke et al., 1987
Brain 7 8±2 44±16 Rezuke et al., 1987
Spleen 22 23±20 Seeman et al, 1985
10 7± 5 37±31 Rezuke et al., 1987
Pancreas 10 8±6 34±25 Rezuke et al., 1987
Hair:c
Japan 457 2.70 Takagi et al, 1986
India 255 0.35
Bulgaria 36 1.92±0.64 Wardet al., 1987
Italy 100 0.43 ± 0.38 Senofonte et al., 1989
Finger nailsb> c 95 0.49 (0.04-7.5) Gammelgaard et al., 1!
Faeces0 10 3.3±0.8 14.2± 2.7 Horak et al., 1973
10 1.5±0.5 Sunderman et al, 1989
a lowest and highest value of the median Ni levels observed in the lung lobes 
b median (range)
c pg/g
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uptake via inhalation due to environmental exposure is estimated as
0.1-0.7 pg/day and about 0.2 mg Ni per year. This is based on the 
assumption that the average person living in an urban centre is exposed 
to approximately 25 ng/m^ of Ni in air and breathes about 20 of air per 
day (ICPS, 1991; Sunderman, 1986; Grandjean, 1984; Niebor et al.,
1988). Cigarette smoking contributes from 1 to 12 pg per pack of 
cigarettes to inhaled Ni (ICPS, 1991; Sunderman, 1986; Grandjean, 1984; 
Niebor et al., 1988). At the work-place, inhalation of Ni fumes and dusts is 
the most important route of absorption (dusts of insoluble Ni compounds, 
aerosols derived from Ni solutions, and gaseous forms containing Ni, 
usually Ni carbonyl). The relative absorption of Ni from the respiratory tract 
depends on the particle size, the chemical form and the 
compartmentalisation within the respiratory tract. Only particles smaller 
than 10 pm in diameter penetrate the alveolar region of the lung. Solid 
particles are partially cleared from the respiratory tract by mucociliary 
action, which in turn results in secondary Ni ingestion. More soluble forms 
are absorbed into the blood stream, whereas elimination of insoluble Ni 
compounds take place to a slower rate. Accumulation in lung tissue and 
regional lymph nodes may occur, although correlation of Ni levels with age 
has not been definitely confirmed (Kollmeier et al., 1985, 1990; Rezuke et 
al., 1987; Raithel et al., 1987, 1988).
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From 1 to 5% of the Ni ingested with the diet is absorbed from the 
gastrointestinal tract, but in fasting human volunteers Ni uptake was much 
higher (27%) (Solomons et al., 1982; Sunderman et al., 1989). Foulkes 
and McMullen (1986a, 1986b) studied the mechanisms of absorption of Ni 
and Cd from the rat jejunum. They reported that both Ni and Cd were 
taken up from the lumen by means of a saturable process, which was 
inhibited by Zn and the constituents of dried skimmed milk. Unlike Cd, Ni 
was not retained in the mucosa and was rapidly released into the body, 
according to a passive process with ion flow occurring in both directions. 
There was no evidence of the presence of Ni carriers on brush borders or 
basolateral membranes.
Nickel is transported in plasma bound to serum proteins and low 
molecular weight compounds. The high molecular weight carriers have 
been identified as albumin and an a2 -macroglobulin, sometimes called 
nickeloplasmin. Laussac and Sarkar (1984) have described a binding site 
of human serum albumin responsible for both Ni and Cu transport. The 
ulterafilterable fraction of serum Ni is associated with aminoacids, mainly 
L-histidine, and small polypeptides. The proportion of Ni bound to the 
different plasma components has not yet been definitely established. The 
results of experiments carried out on rabbit and human serum, in vivo and 
in vitro, showed large variability (Table 1.3).
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Table 1.3 Percentages of serum Ni bound to albumin, nickeloplasmin 
and low molecular weight (LMW) ligands reported in various 
studies
Reference Specie Conditions Albumin Nickelo LMW
________________________________________________ plasmin ligands
Nomoto et al., 1971 Rabbit 40 44 16
Man 34 26 40
Asato et al., 1975 Rabbit in vivo 15
in vitro 36
Nomoto, 1980 Man in vivo 43
Lukassen and Sarkar, 1979 Man in vitro 95.7 0.1 4.2
Niebor et al., 1988 Man in vivo 24
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The values reported for the Ni content of serum and whole blood (Table 
1.1), suggest that Ni is not preferentially accumulated in erythrocytes. 
From the results of in vitro experiments, Niebor et al. (1984, 1988) 
concluded that the presence in serum of high concentrations of albumin 
and aminoacids prevent the accumulation of Ni in the cellular components 
of blood. The distribution of Ni between plasma and blood cell types 
needs to be further investigated.
In animal treated with the radioactive isotope, Ni rapidly appeared in 
kidney, pituitary, lung, skin, adrenal and ovary or testis. Nickel is found in 
all human tissues: analysis of autopsy specimens showed the highest 
concentrations in lung, thyroid and adrenal (Table 1.2).
In experiments on animals, Ni crossed the placenta and was 
transported to the foetus (IPCS, 1991; Lu et al, 1981; Saillenfait, 1993). 
The presence of Ni in human foetal tissue has also been reported as 
indirect evidence of Ni transport through the human placenta (ICPS, 1991; 
Casey and Robinson, 1978). However, the results are high and their 
reliability may be questionable.
Excretion of absorbed Ni occurs mainly in urine, probably bound to low 
molecular weight compounds. Under physiological conditions, Glennon 
and Sarkar (1982) observed an equilibrium between Ni complexes with 
albumin and L-histidine in serum, suggesting that the strong affinity of Ni
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for L-histidine could explain the rapid excretion of Ni in urine after oral or
i.v. administration. From results obtained on the urinary excretion of Ni in 
workers exposed to almost constant levels of Ni in air, Niebor et al (1988) 
proposed the existence of a mechanism for Ni reabsorption in the kidney. 
Rezuke et al. (1987) suggested that biliary excretion may be an additional 
route of Ni elimination, as they observed Ni concentrations in human bile 
comparable to those in urine (Table 1.1). The concentrations for Ni 
content of breast milk and sweat are much higher than urine (Table 1.1). 
However, very few results are available for these excretory pathways.
1.5 HEALTH EFFECTS
Nickel deficiency: Ni is an essential cofactor for some enzymes isolated 
from plants and bacteria (Sigel and Sigel, 1988; Anke et al., 1984) and 
symptoms of Ni deficiency have been reproduced in six animal species: 
chicks, cows, goats, minipigs, rats and sheep. These animals suffered 
reduced haematopoiesis, depressed growth and metabolic alterations 
(Niebor et al., 1988, Anke et al., 1984), when deprived of all dietary Ni, 
the effects being reversed upon addition of Ni at low concentration into 
the diet.
Minimal amounts of Ni may be needed for humans as well, although
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symptoms of Ni deficiency have not yet been demonstrated in man. 
However, Ni is found in low concentrations in all human tissues and fluids 
(Table 1.1 and 1.2) and is transported in human serum bound to specific 
proteins. The narrow concentration ranges observed for Ni in human body 
fluids could suggest homeostatic control. Niebor et al. (1988) claimed that 
reabsorption of Ni occurs in the renal tubular system, probably in the 
proximal tubule. Early reports described increased concentrations of Ni in 
body fluids in pathological conditions, such as cases of acute myocardial 
infarction, unstable angina pectoris, burns, hepatic cirrhosis uraemia and 
rheumatoid arthritis (McNeely et al., 1971; Khan et al., 1984; Leach et al., 
1985; Pedersen and Christensen, 1985), without a known external source 
of extra Ni. However, the values reported for the control groups in some of 
these papers are very high in comparison with more recent estimates and 
the results may be unreliable.
At present, evidence for Ni essentiality in man is far from being 
conclusive. Due to the very low concentrations involved, contamination 
problems may easily lead to erroneous results and misleading 
conclusions.
Nickel toxicity: Acute effects of Ni toxicity have been observed in 
animals, following i.v. or parenteral administration of Ni chloride. These
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include: inhibition of natural killer cell activity and T-cell mediated immune 
response; hyperglycaemia; nephrotoxicity; hepatotoxicity; acute coronary 
vaso-constriction and bronchoalveolar hyperplasia (Sunderman and 
Oskarsson, 1991).
Inhalation of Ni carbonyl (Ni(CO)4 ) results in acute poisoning, which 
may lead to pulmonary lesions and death in the most severe cases. Ni 
carbonyl is a volatile Ni compound, used in the production of high purity 
Ni (Mond process). Due to its high lipid solubility, Ni carbonyl can cross 
cellular membranes, is easily absorbed from the lung and diffuses in all 
organs including brain (IPCS, 1991; Niebor et al., 1988)
Prolonged exposure to vapours of water-soluble nickel salts caused 
chronic respiratory disease, including asthma, bronchitis and 
pneumoconiosis, sometimes associated with hypertrophic rhinitis, 
sinusitis, nasal polyposis and/or perforation of the nasal septum (IPCS, 
1991; Sunderman and Oskarsson, 1991; Niebor et al., 1988).
A higher frequency of neoplasms of the respiratory system and nasal 
sinuses was first recognised in 1928 in workers of a Ni refinery in Clydach 
(Wales). Since then, a number of epidemiological studies on workers in Ni 
refineries, smelters and factories confirmed these findings. Increased 
cancer incidence was mainly associated with operations such as roasting, 
smelting, sintering and electrolytic separation, that involved exposure to
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fumes of metallic Ni and/or dusts of low soluble Ni sulphides and oxides 
(Sunderman, 1984; IPCS, 1991; Niebor etal., 1988).
Increased risk of carcinomas of the larynx, kidney, stomach and soft 
tissue has also been observed in certain groups of exposed workers, but 
the evidence was not conclusive (Sunderman, 1984; IPCS, 1991; Niebor 
et al., 1988).
At present, in most Western countries, limits of less than 1 mg/m^ have 
been adopted for concentration of Ni in air at the work-place (Sunderman 
and Oskarsson, 1991). This measure of occupational hygiene has 
successfully reduced the incidence of cancer among workers.
In vivo and in vitro studies of the mechanism of Ni carcinogenesis 
provided evidence that Ni can act as a cancer promoter and enhance the 
activity of other carcinogenic substances. Nickel forms stable complexes 
with chromatin and induces lesions in nuclear DNA, including: 
conformational transitions, infidelity of DNA synthesis, inhibition of DNA 
synthesis and inhibition of DNA excision repair (Sunderman, 1984; IPCS, 
1991; Niebor et al., 1988; Stinson et al., 1992; Chang et al., 1993; Misra 
et al., 1993). In biological system, complexes with peptides and proteins 
stabilise the trivalent oxidation state for Ni and the activity of the redox 
couple Ni(lll)/Ni(ll) can promote the production of free radicals (Niebor et 
al., 1988; Wang et al., 1993).
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Nickel contact hypersensitivity has been widely documented in both the 
general population and in a number of occupations in which workers were 
exposed to soluble Ni compounds (IPCS, 1991; Liden, 1994). Nickel is 
generally recognised as the most important cause of contact allergy in the 
general population. In a recent multicentre survey of 22 European 
dermatology clinics 19.4% of the patients tested over a period of one year 
demonstrated Ni sensitivity (Menne’ et al., 1991). The incidence of Ni 
hypersensitivity within the general population appears to depend on 
cultural habits, such as fashion and availability of Ni containing objects. In 
Western countries, a marked difference between sexes has been reported 
by all the investigators. Peltonen (1979) and Pryzstowsky et al. (1979) 
observed Ni dermatitis in approximately 10% of the women and 1% of the 
men in samples of population in Finland and the USA, respectively. 
Nielsen and Menne' (1993) found an incidence of Ni hypersensitivity of
11.1% in Danish women compared with 2.2% for men. Fedler and Stromer 
(1993) reported Ni hypersensitivity in 15.3% of the women and 5.3% of 
the men in a sample of Swiss healthy subjects. In Canada, Nethercott and 
Holness (1990) observed a positive reaction to Ni sulphate in 16.7% of 
the women and 5.1% of the men in a sample of 1074 subjects with 
suspected contact dermatitis. However, in Nigeria, approximately the 
same percentage of women (12.4%) and men (11.7%) were affected by Ni
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dermatitis, as wearing necklaces and bracelets was equally fashionable 
among both sexes (Olumide, 1985). In an early report from Kuwait the 
ratio women to men for Ni hypersensitivity was 1:3 (Kanan, 1969). This 
unusual finding was attributed to increased sensitisation of men through 
watch straps and clothes accessories, whereas, at the time, very few 
women in Kuwait wore cheap jewellery.
The higher frequency of Ni sensitivity in Western women compared 
with men has been attributed to higher exposure through costume 
jewellery and kitchen utensils. Ear piercing has been strongly associated 
with increased frequency of Ni dermatitis (Boss and Menne’, 1982; 
Larsson-Stymne and Widstrom, 1985; McDonagh et al., 1992; Nielsen 
and Menne', 1993; Rasanen et al., 1993). In a recent study, Nielsen and 
Menne’ (1993) reported that both the association of age (inverse) and 
female sex (direct) with increased frequency of Ni positive patch tests 
disappeared when data were adjusted for the effect of ear piercing.
Sensitisation occurs after localised exposure of the skin to Ni ions, that 
penetrate the skin and conjugate with proteins to form the antigen. 
Microvescicular hand eczema is the most common clinical manifestation 
of Ni dermatitis. After the first outbreak, Ni hypersensitivity is likely to last 
a lifetime and affect quality of life and ability to work.
Besides allergic reactions at the site of contact, generalised secondary
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eruptions may occur without known contact with Ni. The response to oral 
challenge with Ni salts gave contradictory results (Cronin et al., 1980; 
Gawkrodger et al., 1986), whereas the ingestion of a diet naturally high in 
Ni for 4 days induced an exacerbation of hand eczema (IPCS, 1991). 
Although some patients benefited of the reduction of dietary intake of Ni 
(Veien et al, 1993; Atakan et al., 1993), others reported lowered degree of 
allergy following repeated administration of oral doses of Ni sulphate 
(Sjovall et al., 1987; Santucci et al., 1988, 1994).
At present, owing to the widespread use of nickel in a variety of 
commodities of everyday use, an increasing number of the general 
population may be at risk of Ni sensitisation and little can be done to 
improve this pathological condition. Both reduced Ni intake and repeated 
Ni oral administration have been reported to produce some benefit in 
some of the patients, but the mechanisms responsible for these 
controversial responses are not known. The understanding of Ni 
dermatitis could profit from improved knowledge of Ni metabolism in 
healthy and sensitive subjects.
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1.6 ANALYTICAL METHODS OF NICKEL DETERMINATION IN 
BIOLOGICAL MATERIALS
The investigations of Ni metabolism and toxicity requires the 
determination of Ni levels in biological materials. Since in most of the 
specimens of interest, the concentrations to be analysed are low and the 
risk of contamination is high, achieving reliable results is still a difficult 
task.
The reliability of the analytical measurement alone is not enough to 
assure the reliability of overall results. Procedures of sample collection, 
sampling and storage of the samples should be carefully designed and all 
possible sources of contamination considered and kept under control. 
Sample pretreatment should be kept to a minimum and carried out under 
clean conditions, preferably within a laminar flow workstation. Several 
aspects of the analysis of Ni in various biological materials have been 
reviewed in detail (IUPAC, 1980; Stoeppler, 1984a; Stoeppler, 1984b; 
Seiler, 1988; IUPAC, 1994).
Of the techniques available for the determination of trace elements, 
graphite furnace atomic absorption spectrometry (GFAAS), differential 
pulse adsorption voltammetry (DPAV) and inductively coupled plasma 
mass spectrometry (ICP-MS) are the most sensitive. Flame atomic
27
absorption spectrometry, inductively coupled plasma atomic emission 
spectrometry and neutron activation analysis can only be used for high 
concentrations or after enrichment procedures. Detection limits for various 
techniques are reported in Table 1.4.
At present, GFAAS is the technique of choice for the analysis of Ni in 
most biological materials. This method is simple, rapid and requires a 
minimal manipulation of the sample, thus reducing the risk for 
contamination. Detection limits as low as 0.45 pg/L for urine, 0.1 pg/L for 
whole blood and serum and 10 ng/g dry weight for tissues, food and 
faeces have been reported (Sunderman et al., 1984, 1985, 1986). 
However, according to a recent report, Ni concentrations in serum of 
healthy subjects appear to be lower than 0.1 pg/L and even more 
sensitive methods are needed.
Differential pulse adsorption voltammetry offers the highest sensitivity 
for the determination of Ni (Table 1.4). Accumulation of Ni at the working 
electrode/solution interface is obtained by adsorption in the presence of a 
suitable complexing agent such as dimethylglyoxime. The main 
disadvantage of this procedure is the need for complete mineralisation of 
biological samples, to avoid interferences with the adsorption process. 
Since typical Ni content of mineralised blank solutions is about 0.1 ng/ml, 
this step dramatically reduces the actual detection limits for the
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Table 1.4 Detection limits reported in literature for different analytical 
techniques for the determination of Ni in aqueous solutions.
Method Detection limit, ng/ml Reference
FAAS 30 Perkin-Elmer Operator's Manual
RNAA 10 Nuclide: 65Ni, Stoeppler, 1984
ICP-AES 1-5 Que Hee et al., 1985
GFAAS 0.15 This study, ch. 2
Z-GFAAS 0.06 Nixon et al., 1989
ICP/MS 0.03 Horlick et al., 1987
DPAV 0.001 Ostapczuk, 1983
DPAV = Differential Pulse Adsorption Voltammetry
FAAS = Flame Atomic Absorption Spectrometry
GFAAS = Graphite Furnace Atomic Absorption Spectrometry
ICP-AES = Inductively Coupled Plasma -Atomic Emission Spectrometry
ICP/MS = Inductively Coupled Plasma -Mass Spectrometry
RNAA = Radiochemical Neutron Activation Analysis
Z-GFAAS = GFAAS with Zeeeman background correction
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determination of Ni in biological materials by this procedure.
Recently, techniques based on mass spectrometry (MS), such as gas 
chromatography/MS and inductively coupled plasma/MS have been 
applied to the determination of Ni in serum and urine (Aggarwal et al., 
1989; Vaughan and Templeton, 1990; Xu et al., 1993). Although the 
sensitivity of these procedures may not be optimal and sample 
pretreatment to overcome matrix interferences may appear cumbersome, 
the development of such methods which are able to detect the isotopic 
composition of the sample is important for the use of stable isotopes in 
both analytical and metabolic investigations.
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CHAPTER 2
CLINICAL TOXICITY OF NICKEL
2.1 INTRODUCTION
Due to the widespread uses of Ni and Ni alloys, patients undergoing 
invasive medical treatments may be at risk of adverse effects from 
exposure to Ni. Acute intoxication and severe allergic reactions occurred 
after haemodialysis with fluids inadvertently contaminated with Ni 
(Webster, 1980; Olerud, 1984). Internal exposure to Ni contained in 
implants, such as cardiac pacemakers, orthodontic and orthopaedic 
prostheses, caused allergic reactions and sometimes required further 
surgery to remove and substitute these items with others made with Ni- 
free alloys (Fisher, 1977; Landwehr and Van Ketel, 1983; Waterman and 
Schrik, 1985; Fernandez et al., 1986; Burden and Eedy, 1991; Trombelli 
et al., 1992; Guyuron and Lasa, 1992; Lowey, 1993). Even the use of a 
stainless steel needle induced the development of contact dermatitis in a 
sensitive subject (Romaguera and Grimalt, 1985).
Patients with chronic renal failure maintained on haemodialysis have
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higher concentrations of Ni in serum (Drazniowsky et al., 1985; Wills et 
al., 1985; Hopfer et al., 1985; Hopfer et al., 1989; Nixon et al., 1989) and 
subjects who had undergone total hip replacement had increased urinary 
excretion of Ni, Co and Cr due to corrosion and leakage from the 
prostheses (Hennig et al., 1992).
Nickel concentrations in serum and urine were increased in patients 
with chronic alcoholism treated with disulfiram. This effect was attributed 
to chelation of dietary Ni by diethyldithiocarbammate, a metabolite of 
disulfiram, and enhanced gastrointestinal absorption of this lipophilic Ni 
complex (Hopfer et al., 1987).
Considerable amounts of potentially toxic metals, including Ni, may 
contaminate pharmaceuticals, nutrient solutions and blood products for 
intravenous (i.v.) injection (Milliner et al., 1985; Leach and Sunderman, 
1985; Fell et al., 1986; Fell and Maharaj, 1986; Leach and Sunderman, 
1987; Diver et al., 1988; Koppel et al., 1988; Gammelgaard and 
Sandberg, 1989).
Iatrogenic exposure to Ni clearly poses a risk for hypersensitive 
subjects, but even if clinical signs of Ni toxicity do not appear, the long 
term consequences of internal exposure to Ni are not known. Since Ni is 
mainly excreted through the kidney, the elderly and other subjects with 
reduced renal function, including pre-term babies with immature kidneys,
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may accumulate Ni in tissue with possible adverse effects.
This study was aimed to contribute to the understanding of the possible 
sources of Ni exposure within medical care and focused on two points: the 
assessment of the contamination with Ni of human albumin solutions 
(HAS) for i.v. administration and the evaluation of hypernickelaemia in 
haemodialysed patients.
2.2 NICKEL AND OTHER TRACE METALS 
IN HUMAN ALBUMIN SOLUTIONS
Human albumin solutions were originally developed as an alternative to 
blood or reconstituted dried human plasma for the treatment of casualties 
during the second World War. Since then, they have been widely used in 
medicine. The conventional therapeutic indications for albumin 
administration are (McLelland, 1992):
• to replace plasma volume (intravascular expansion replacement) and 
achieve target values of osmotic colloid pressure or albumin 
concentration (i.e. in patients with trauma or undergoing major 
elective surgery);
• to reduce the loss of fluids and proteins observed in burns owing to
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prolonged increase in microvascular permeability;
• for extracorporeal circulation during cardiac surgery;
• to achieve diuresis in patients with nephrotic syndrome resistant to 
diuretics;
• to replace massive protein loss in cirrhotic patients being treated with 
abdominal paracentesis.
• for therapeutic plasma exchange.
Plasma exchange, i.e. the selective removal of the patient's plasma 
and its replacement with donor's plasma or another suitable colloid, has 
been applied in a number of diseases to remove or reduce the 
concentration of some pathological factors in blood. Table 2.1 lists 
diseases for which plasma exchange has proven beneficial and those for 
which clinical advantages are uncertain (Shumak and Rock, 1984). 
Human albumin solutions or purified plasma fraction are often used as the 
replacement fluid instead of donor’s plasma, to avoid the risk of hepatitis 
and other viral infections. Exchanges in which the volume replaced 
approaches the patient's plasma volume are repeated four or five times 
within seven to ten days for effective therapy. In such cases, patients may 
receive from 10 to 15 litres of HAS (Shumak and Rock, 1984).
In 1985, Milliner et al. observed that HAS were heavily contaminated 
with aluminium and could pose a risk for patients with renal dysfunction.
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Table 2.1. Disorders commonly treated with plasma exchange (PE), 
with proven or uncertain efficacy (Shumak and Rock, 1984).
Well- established indications for PE:
Hyperviscosity syndrome
Cold antibody-type autoimmune haemolytic anemia 
Post-transfusion purpura
Factor VIII antibody unresponsive to Factor VIII therapy 
Myasthenia gravis 
Refsum's disease 
Goodpasture's syndrome
Indications for PE needing further assessment:
Prevention of hemolytic disease due to Rh antibody
Thrombotic thrombocytopenic purpura
Idiopathic thrombocytopenic purpura
Cryoglobulin-induced disease
Preparation for bone-marrow transplantation
Familial hypercholesterolemia
Acute and chronic relapsing Guillain-Barre' syndrome
Multiple sclerosis
Rheumatoid arthritis
Systemic lupus erythematosus
Rapidly progressive glomerulonephritis
Renal-allograft rejection
Biliary cirrhosis
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Human albumin solutions are often administered to patients with renal 
disease, to expand intravascular volume in patients undergoing 
haemodialysis and to promote diuresis in subjects with severe nephrotic 
syndrome. A variety of disorders that benefit from plasma exchange 
therapy are associated with renal insufficiency, including
cryoglobulinemia, systemic lupus erythematosus, Goodpasture’s 
syndrome, rapidly progressive glomerulonephritis, thrombotic 
thrombocytopenic purpura and renal-allograft rejection (Milliner et al., 
1985).
Fell et al. (1986) reported Al contamination of pharmaceuticals, 
nutrients and blood products used for i.v. administration and Maharaj et 
al. (1987) described Al bone disease in patients receiving contaminated 
HAS during plasma exchange therapy.
Leach and Sunderman (1985) observed that HAS is also prone to 
contamination with considerable amounts of Ni, due to the high affinity of 
albumin for this metal. Sunderman (1983) strongly recommended 5 pg/L 
as the maximum allowable concentration of Ni in common fluids for i.v. 
injection and 10 pg/L for HAS and solutions containing aminoacids, since 
acute allergic and cardiovascular reactions may occur after i.v. Ni 
infusion.
Fell and Maharaj (1986) described widely varying concentrations of
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potentiaHy toxic metals in both HAS and other colloid solutions. They 
found values 10 to 1000 times higher than normal serum reference values 
for Al, Cr, Mn, Ni and Fe; marked depletion of Mg, Cu, Zn and Se; and an 
excess of Ba and Sr. In a following paper Diver et al. (1988) reached 
similar conclusions analysing the content of trace elements present in two 
commercial plasma protein and solutions, although the levels of 
contamination and depletion were rather different for the two products. 
This considerable contamination was attributed to the ’scavenging action' 
of proteins in contact with stainless steel surfaces during the production 
stages, impurities of the chemicals used during the manufacturing 
process and leakage from metal and rubber closures of the containers 
(Fell and Maharaj, 1986).
Koppel et al (1988) investigated the influence of three weeks of daily 
HAS infusion on metal blood concentrations of eight critically ill patients 
with acute renal failure, protein catabolism, ventilator therapy and 
haemodialysis treatment. They reported increased blood Ni 
concentrations and computed that the Ni dose due to HAS infusion 
ranged from 5 to 70 MO^ay, i.e. higher than the estimated amount 
absorbed daily from the diet by healthy subjects. Nickel and chromium 
concentrations in HAS were also increased to 5 and 8 mg/L, respectively, 
after 24 h contact with the metal cannulas sometimes used for infusion.
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Following the earlier reports on the Al content of HAS, efforts have 
been made to identify the sources of metal contamination during the 
manufacturing process. The impurities contained in some of the reagents 
used, such as sodium hydroxide and caprylic acid, and the depth filtration 
stages appeared as the principal causes of the increased concentration of 
some trace metals in 5% HAS (Maharaj, 1986; Gammelgaard and 
Sandberg, 1989). Gammelgaard and Sandberg (1989) reported that depth 
filtration steps where in some cases performed with filters coated with Al 
compounds. In addition, both Al and Ni levels showed a further dramatic 
increase during the concentration process of albumin from 5% to 20%.
In most cases, actions were taken to reduce metaf contamination. At 
the Edinburgh Protein Fractionation Centre, contaminated reagents were 
identified and substituted or purified, filters were washed with citrate 
solutions before use and a further step of ultrafiltration was introduced, to 
selectively remove contaminant metals both as ions and bound to low 
molecular weight compounds. These changes proved successful for the 
substantial reduction of the concentrations of Al, Mn and Cr to less than 
20% of the initial values, but most of the Ni (75%) was retained because 
of the high affinity for albumin. Therefore, Ni remained a possible hazard 
for patients receiving HAS (Maharaj, 1986).
Following these early investigations, improved technology for metal
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contamination control has been adopted by manufacturers, such as the 
substitution of stainless steel with plastic equipment whenever possible. 
Therefore, there was a need to assess the present concentration of Ni 
and other metals in commercially available HAS and verify the sources of 
potential contamination during the manufacturing process. This was 
accomplished by analysing a number of HAS of different origin and 
studying the profile of selected trace metals by means of semiquantitative 
ICP-MS in HAS and in samples from various stages of the production 
process.
2.2.1 Experimental
Blood products: Samples of human plasma protein solutions (PPS,
85% albumin) and human albumin solutions (HAS) were kindly donated
by manufacturers (Protein Fractionation Centre, Scottish Blood
Transfusion Service, Edinburgh, Scotland; Farmabiagini, Castelnuovo di
Garfagnana, Italy; Istituto Sclavo, Siena, Italy) or otherwise obtained from 
*
the Glasgow Royal Infirmary (GRI) pharmacy. Other human blood 
products (Factor VIII, Factor IX and immunoglobulin) were also obtained 
from the GRI pharmacy.
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Samples from various stages of the production process of PPS at the 
Protein Fractionation Centre were kindly provided by Dr W. McBey. 
Selected plasma proteins are obtained by cold/ethanol fractionation. A 
simplified scheme of the purification process and the points where 
samples were taken for analysis is shown in Fig. 2.1.
Nickel analysis: Ni determinations were carried out by graphite furnace 
atomic absorption spectrometry (GFAAS), using a Perkin-Elmer atomic 
absorption spectrophotometer, mod. 1100, with deuterium arc background 
correction, equipped with an AS-70 autosampler. Graphite tubes were 
pyrocoated. Signals were recorded as peak area by a built-in 
computerised system. Instrumental conditions were as follows: lamp 
current: 15 mA; wavelength: 232.0 nm; slit: 0.2 nm; integration time: 4 s. 
The graphite furnace programme is reported in Table 2.2. The injection 
volume was 50 pi. All samples were diluted 1+2 with a diluent solution 
containing 1% v/v HNO3 and 0.25% Triton X-100. Aqueous Ni solutions 
were used for calibration. Solutions containing more than 200 g/L of 
albumin were diluted 1+4 and longer drying and ashing steps were used. 
Analysis of solutions with high Ni content was performed using smaller 
injection volumes (10-20 pi) and a less sensitive wavelength (301.5).
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HUMAN PLASMA (S1)
FROZEN AT -30°C, THAWED ===>FVIII
+ ACETATE BUFFER ===>
+20% ETHANOL ===>
FILTRATION
+ 40% ETHANOL ===>
FILTRATION
(S2)
(S3)
====> 1ST PROTEIN FRACTION
(S4)
====> 2ND PROTEIN FRACTION
RESOLUTION
STERILE ULTRAFILTRATION
DILUTION
ADDITION OF NaCI AND STABILIZERS
(sodium caprylate)
PASTEURIZATION AT 60°C
FINAL PRODUCT (PPS, 45-48%)
(55)
(56)
(57)
(58)
(S9)
Fig. 2.1 Scheme of the production of PPS at Edinburgh Protein 
Fractionation Centre and points where samples were 
withdrawn (S1 to S9)
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Table 2.2 Furnace programme for the determination of Ni in 
HAS by GFAAS
STEP 1 2 3 4 5 6
TEMP, °C 130 180 700 1200 2600 2700
RAMP TIME, s 5 25 10 10 0 1
HOLD TIME, s 10 5 20 20 5 2
READ on
GAS FLOW, ML/MIN 300 300 300 300* 0 300
* Gas flow =0 for the last 5 s in this step
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ICP-M S analysis: Multielemental semiquantitative determinations were 
performed on some of the samples by ICP:MS using a PLASMAQUAD 
instrument (VG Elemental, Winsford, Cheshire, UK) at the Scottish 
Universities Research Reactor Centre. All specimens were diluted 1+9 
with 1% HNO3 . Indium (50 pg/L) was used as internal standard. All 
measurements were corrected for blank using a 1% HNO3 solution.
Control o f contamination: due to avid binding of Ni by albumin 
solutions, precautions were taken during the whole analytical procedure 
to avoid contamination. All plastic ware, including autosampler cups, were 
soaked in 20% HNO3 overnight and rinsed six times with purified water. 
Micropipette tips were washed with 20% HNO3 and rinsed three times 
with water before use. Pretreatment of samples expected to have low 
concentrations of Ni were carried out in a laminar flow hood. Nitric acid 
used for analysis (Aristar, BDH) was further purified by subboiling in 
PTFE bottles.
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2.2.2. Results
Analytical performance of GFAAS method: the detection limit (three 
times the value of the SD of 12 measurements of a blank solution) was 
0.9 |jg/L. The slopes of calibration curves obtained with aqueous and HAS 
based standards did not differ (y=1.4 + 1.69x for aqueous standards 
versus y=1.6 + 1.67x for HAS based solutions). Analytical recovery of Ni 
added to a 20% HAS containing 7.3 pg/L Ni, was 102 ± 5%. Within-day 
and between-day precision, obtained from replicate analysis of a 5% HAS 
containing 13.6 pg/L Ni, were 3% (n = 8) and 6 % (n = 10), respectively.
Contamination of HAS with Ni and other metals: The Ni concentrations 
in HAS produced over a period of time by various manufacturers are 
reported in Table 2.3. Table 2.4 lists the Ni content of other blood 
products. Figure 2.2 shows the dramatic change in Ni concentration in 
HAS produced in the same centre from 1988 to 1992. In Figure 2.3 the 
results obtained in this study are compared with those of earlier 
investigations.
Semiquantitative information on the concentration of other metals in 
samples of PPS and HAS produced by different manufacturers and in 
different countries (Scotland, England and Italy) are reported in Table 2.5.
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Table 2.3 Concentration of Ni and Co observed in different brands of 
HAS.
CODE BRAND BATCH N. EXPIRE
DATE*
ALBUMIN
g/L
N Ni
pg/L
Co
pg/L
H BPL FEB 91 45 1 97.8 5.3
B IMMUNO JAN 91 43 1 7.4 0.8
C IMMUNO AUG 92 43 1 13.8
D ARMOUR NOV 91 50 1 8.3
G ARMOUR MAG 92 50 1 9.7
E SBTS, PPS APR 91 45 1 370 13
A1 SBTS, PPS JUN 91 45 1 430 17
F SBTS, PPS JUL91 45 1 65 1.1
A SBTS, PPS AUG 91 45 1 20.4 0.7
I SBTS, PPS OCT 91 45 1 13.5 0.4
L SBTS, PPS NOV 94 45 1 13.6 0.8
ED24 SBTS, PPS SEP 96 45 1 5.2
ISS1-3 FARMAITALIA 922617 JUL 95 50 3 8
ISS4-6 FARMAITALIA 924004 JUL 95 50 3 8.6
KAG KABI (Germany) DIC 87 200 1 59 0.9
KAS KABI (Sweden) MAR 87 200 1 33
SHA1 SBTS SEP 88 200 1 1020 37
SHA2 SBTS DEC 92 200 1 28
SHA3 SBTS JAN 93 200 1 33
ZEN BIO-PRODUCTS JAN 95 200 1 7.3
LAB
ISS7-9 FARMABIAGINI 923324 JUL 95 250 3 40.6
ISS10-12 FARMABIAGINI 923323 JUL 95 250 3 39.5
ISS13-14 SCLAVO AS2=411 APR 95 200 3 41.9
ISS7-9 SCLAVO AS2=412 APR 95 200 3 43.7
BPL = BLOOD PRODUCT LAB
SBTS = SCOTTISH BLOOD TRANSFUSION CENTRE
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Table 2.4 Nickel concentration in other human blood products 
for intravenous injection.
BLOOD PRODUCT________________ BRAND EXP. DATE Ni, ug/L
IMMUNOGLOBULIN SBTS JUN 93 10
ANTIHAEMOPHILIC FACTOR SBTS JUL 93 32
FACTOR IX CONCENTRATE SBTS MAY 93 8
SBTS = SCOTTISH BLOOD TRANSFUSION CENTRE
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500
400
3 0 0 -
O)
200 -
100 -
4/88 6/88 7/88 8/88 10/88 11/91 9/92
Month/year of production
Fig. 2.2 Ni content of HAS (5%) produced at the Edinburgh Protein 
Fractionation Centre between 1988 and 1992 compared 
with the suggested limit of 10/ig/L (—).
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The variations of the metal content in the various stages of the production 
process of PPS at Edinburgh Protein Fractionation Centre are reported in 
Table 2.6 and Figs. 2.4-2.12. Since Ni and other elements are strongly 
bound to proteins, the variations of the total protein content at stages of 
the process are reported for comparison.
2.2.3 Discussion
Results presented in Tables 2.3 and 2.4 confirm the contamination of 
HAS and other blood products with Ni. Some of the oldest batches 
contained Ni concentrations as high as 1020 pg/L and there was large 
variability among manufacturers.
The Ni content of PPS produced at the Edinburgh Fractionation Centre 
from 1988 and 1992 showed an impressive reduction (Fig. 2.2), although 
only in 1992 did it reach the limit of 10 pg/L recommended by Sunderman 
(1983) for solutions for i.v. injection containing albumin. The improvement 
of the quality of HAS now commercially available is further highlighted by 
the comparison of results obtained in this study for 20% HAS with those of 
earlier investigations (Fig. 2.3). The Ni content of batches of 20% HAS 
produced in both Scotland and Italy in 1992 was close to 40 pg/L. This 
value, adjusted for concentration, was comparable to the amount of less
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than 10 pg/L found in 5% HAS from the same producers. In earlier 
reports, Ni content ranged from 24 to 497 pg/L. However further reduction 
of Ni concentration is possible, since a sample of HAS produced by 
Bioproducts Lab (England) contained only 7.4 pg/L of Ni.
Preliminary results were obtained by ICP-MS on the concentration of 
Co, also a constituent of stainless steel, in a few samples of HAS. Cobalt 
concentrations were high in samples with very high concentrations of Ni 
and decreased to less than 1 pg/L in samples where Ni concentrations 
were also reduced. This may suggest a common'origin for at least some 
of the Ni and Co contamination (Table 2.3).
The concentration of other metals, determined by semiquantitative ICP- 
MS, was very variable for samples of different origin and different content 
of albumin (Table 2.5). Semiquantitative analysis by ICP-MS provides 
qualitative information over a range of selected elements with an accuracy 
within 30% (Vaughan et al., 1991). Aluminium values ranged from 31 to 
38 pg/L for samples containing 5% of albumin and from 82 to 580 pg/L for 
samples containing more than 200 g/L of albumin. Also Ba, Sr and W 
concentrations were increased, whereas essential elements such as Br, 
Cu and Rb were depleted. Zinc was lower than 0.3 mg/L in some of the 
samples but as high as 3 mg/L in HAS of Italian origin.
During the manufacturing process, Ni concentration (Table 2.6,
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Fig. 2.4 Concentration of Ni (triangles)
and total protein (circles) in various 
stages of the production of PPS.
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Fig. 2.5 Concentration of Al (triangles)
and total protein (circles) in various 
stages of the production of PPS.
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Fig. 2.6 Concentration of Ba (triangles)
and total protein (circles) in various 
stages of the production of PPS.
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Fig. 2.7 Concentration of Br (triangles)
and total protein (circles) in various 
stages of the production of PPS.
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Fig. 2.8 Concentration of Cu (triangles) 
and total protein (circles) in various 
stages of the production of PPS.
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Fig. 2.9 Concentration of Rb (triangles) 
and total protein (circles) in various 
stages of the production of PPS.
58
Rb
, 
/jg
/L
To
ta
l 
pr
ot
ei
n,
 g
/L
120 100
9 0 - -75
6 0 - -50
3 0 - -25
S1 S2 S3 S4 S5 S6 S7 S8 S9
Stages
Fig. 2.10 Concentration of Sr (triangles)
and total protein (circles) in various 
stages of the production of PPS.
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Fig. 2.11 Concentration of W (triangles)
and total protein (circles) in various 
stages of the production of PPS.
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Fig. 2.12 Concentration of Zn (triangles)
and total protein (circles) in various 
stages of the production of PPS.
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Fig. 2.4) showed a sharp increase after the buffer addition (S2), then 
followed the decrease of protein concentration, due to ethanol addition 
and protein precipitation (S3). After the filtration steps, Ni concentrations 
were further increased in both the supernatant (S4) and the separated 
protein fraction containing albumin (S5). The ultrafiltration removed only a 
small amount of Ni (S6 ), whereas the rest was tightly bound to albumin 
(S7, S8). A further increase of Ni concentration occurred in the last step, 
which included the concentration of proteins from 4.3 to 4.7%.
Other metals showed a different behaviour. Large amounts of Al, Ba 
and Sr (Table 2.6, Figs. 2.5, 2.6 and 2.10) were absorbed during the 
filtration steps, but were efficaciously removed by ultrafiltration. The final 
Sr concentration was actually lower than the initial concentration. 
Bromine, Rb and Zn (Table 2.6, Figs. 2.7, 2.9 and 2.12) were 
continuously depleted during the process, whereas Cu (Table 2.6, 
Fig. 2.8) was only partially lost. Traces of W were present during the 
whole process but the concentration in the final product did not 
exceed 40 pg/L.
At present, HAS produced in at least two European countries (UK and 
Italy) meets desirable standards of quality with regard to Ni concentration. 
Comparable performances are likely to be obtained in countries who 
adopt similar procedures, although the risk of contamination should not be
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underestimated. For other metals, especially Al, large variability still exists 
between different manufacturers and batches (Table 2.5).
From the investigation of the production process at the Edinburgh 
Fractionation Centre, I found that the sources of Ni contamination were 
the same as described in earlier studies (Maharaj, 1986; Gammelgaard 
and Sandberg, 1989), but the extent of the contamination was much lower 
with a Ni content in the final product of only 5.1 pg/L. The filters were 
found to release considerable amounts of metals, whereas most of the 
loss of trace elements such as Cu and Zn is likely to be due to the 
removal of their carrier-proteins. Since the final Zn content in some of the 
products was very high, leakage from the glass bottles and rubber closure 
should also be considered as a source of contamination.
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2.3 HYPERNICKELAEMIA IN PATIENTS WITH CHRONIC RENAL 
FAILURE MAINTAINED ON HAEMODIALYSIS
Patients with chronic renal failure (CRF) undergoing regular 
haemodialysis may experience depletion of essential elements as well as 
uptake of toxic metals present as contaminants in the dialysis fluids.
The accumulation of Al is a recognised cause of various haemodialysis- 
related syndromes and the uptake of other toxic elements has also been 
of concern.
Salvadeo et al. (1979) measured the concentration of 15 elements in 
the fluid entering and leaving the dialyzer and found a significant reduction 
in seven potentially toxic metals, including Ni.
Acute Ni intoxication occurred in 23 dialysed patients, who reported 
symptoms of nausea, vomiting, weakness and palpitations, due to the 
elution of Ni from a Ni-plated stainless-steel heater into the water supply 
used to prepare the dialysis fluid (Webster et al., 1980).
Olerud et al. (1984) observed acute allergic reactions to Ni during 
haemodialysis in a patient with Ni hypersensitivity. The apparent source 
of Ni was a stainless steel fitting in a bicarbonate delivery system. In 
'in vitro' experiments, Olerud et al. (1984) demonstrated that Ni was 
extracted from the dialysis fluid into the blood. This observation was
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consistent with the high affinity of albumin for Ni. After a single 
haemodialysis cycle, plasma Ni concentration was 89% higher than in the 
original dialysis fluid.
Drazniowsky et al. (1985) found increased Ni concentrations in 16 
patients who were undergoing regular haemodialysis for 1 to 69 months 
when compared to 71 healthy controls.
Wills et al. (1985) investigated the Al and Ni content of serum and 
lymphocytes in long-term haemodialysed patients. Serum Ni 
concentrations were higher in patients than controls; in contrast, there 
was no significant difference in the Ni concentration of lymphocytes 
between the two groups. Wills et al. (1985) concluded that Ni was not 
retained in tissue. However, due to the very low amounts present, 
contamination or analytical difficulties may have obscured such a finding.
Hopfer et al. (1985, 1989) carried out an extensive study of Ni 
concentrations in serum of patients with CRF attending different dialysis 
facilities. Hypemickelaemia was a consistent finding in all the 
haemodialysed patients. Only one of 7 subjects with CRF not undergoing 
dialysis had elevated serum Ni compared with controls. Hopfer et al. 
(1985) found increased serum and whole blood Ni concentrations after a 
single dialysis cycle and observed the reduction of serum Ni 
concentrations in patients when water of improved purity was used to
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make up the dialysis fluid.
Nixon et al (1989), using improved methodology and strict 
contamination control, observed values of Ni in serum ranging from 1.5 to 
18.9 pg/L in patients maintained on dialysis, whereas the average serum 
Ni concentration in their controls was 0.14 ± 0.09 pg/L.
Hosokawa et al. (1987a) reported lower Ni concentrations in subjects 
undergoing dialysis, compared with an average value of 5.6 ±0.8 pg/L in 
controls, and a significant correlation between dialysis anaemia and 
serum Ni concentrations (1987b).
These results suggest some positive evidence of Ni transport between 
the dialysis fluid and blood, even against a concentration gradient. The 
results of these investigations are contradictory and no correlation was 
found between Ni concentrations and length of therapy, age or sex of the 
subjects. Little is known about the mechanisms of Ni uptake during 
dialysis and its metabolic fate in patients with impaired renal function.
The observation that most of the patients maintained on haemodialysis 
have hypemickelaemia suggests that Ni is either absorbed during dialysis 
or not completely removed from the body by this treatment and may 
accumulate in bone and tissues. Hopfer et al. (1985) highlighted the 
similarity between a number of disorders observed in patients undergoing 
long-term haemodialysis and effects observed in rodents after parenteral
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administration of NiCl2 such as lipid peroxidation (Giardini et al., 1984), 
impaired cellular and humoral immunity (Graham et al., 1978; Donnelly et 
al., 1983; Smialowicz et al., 1984), and hyperprolactinaemia (Clemons 
and Garcia, 1981; Mastrogiacomo et al., 1984).
The clinical significance of Ni in haemodialysis may have been 
confounded by factors such as the limited number of subjects studied, the 
high risk of contamination and the difficulties of Ni analysis at low 
concentrations.
In recent years, efforts have been made to meet requirements of purity 
for dialysis fluids and concentrates, in agreement with the EEC resolution 
on protection of haemodialysed patients from Al toxicity (Council of the 
European Communities, 1986). Therefore, risk of contamination from other 
metals may also be reduced and the extent and the causes of 
hypemickelaemia in haemodialysed patients may need to be 
reconsidered.
Nowadays, improved analytical methodologies and means of 
contamination control are available to a larger number of laboratories. 
Nixon et al. (1989) needed^o carry out sample preparation and analysis of 
serum Ni in a 'class 100' clean environment, to accurately determine 
reference values in a normal population. However, the analysis of the 
higher concentrations of Ni expected in haemodialysed patients could be
67
carried out under less strict conditions, provided that there is careful 
control of contamination during sample collection and analysis.
I assessed the performance of a method for serum Ni analysis, based 
on graphite furnace atomic absorption spectrometry with deuterium-arc 
background correction (D2-GFAAS). This instrumentation is available to a 
larger number of laboratories than Zeeman corrected GFAAS (Z-GFAAS), 
used in the most recent methods (Sunderman et al., 1984; Andersen et al., 
1986; Nixon etal., 1989).
I also measured the concentrations of serum Ni in a group of 25 
patients undergoing regular haemodialysis and investigated the effect of a 
single dialysis cycle on serum Ni concentrations.
2.3.1 Experimental
Subjects: Blood samples were obtained from 25 patients with end-stage 
chronic renal failure ( 18 men and 7 women, age 22 to 78 years, 
mean ± s.d.: 53 ± 17 years), who had been treated by haemodialysis three 
times a week at the Renal Unit of Glasgow Royal Infirmary for an average 
of 42 ± 59 months (range >1-290 months).
Dialysis was performed with equipment from Gambro Dialysatoren, 
GmbH & Co, Munich, Germany and Fresenius AG, Munich, Germany,
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using capillary flow dialysers with Cuprophan membranes (Baxter 
Healthcare Ltd, England, CF ST15, membrane surface 0.9 m^, and CF 
ST23, membrane surface 1.25 m^) or cellulose acetate hollow fibre 
dialysers (Baxter, CA150, membrane surface 1.5 m^). Conventional 
electrolyte concentrate solutions, manufactured by Gambro and 
Fresenius, respectively, were diluted 1+34 with water purified by reverse 
osmosis.
Serum Ni concentrations were also measured in a control group of 8 
women with normal renal function, age 29 to 73 years (mean ± s.d.: 48 ± 
19 years), who were receiving total parenteral nutrition (TPN) and being 
monitored for essential trace element status.
Contamination control: Due to the ubiquitous presence of Ni in the 
environment and the 'scavenging' properties of human albumin, strict 
precautions were taken to avoid contamination of samples during the pre- 
analytical and analytical phases. Ultrapure HNO3 , 65%, ('Aristar', BDH), 
was further purified by subboiling in PTFE bottles. Ultrapure water was 
obtained by a four-stage purification using ion-exchange (Elgastat UHP, 
Elga, High Wycombe, U.K.). All plastic-ware (i.e. tubes, Pasteurs, AAS 
cups) were soaked overnight in 20% HNO3 , rinsed thoroughly six-times 
with ultrapure water, dried in a laminar flow hood and stored in clean
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plastic bags until use. Pipette tips were rinsed three times with 20% HNO3 
and ultrapure water before use. Manipulation of samples was carried out 
in a laminar flow hood.
Blood collection: Blood samples were obtained before dialysis directly 
from the intra-arterial cannula. To avoid contamination from needles, the 
first 10 ml of blood were collected for routine analyses, then another 10 ml 
aliquot was withdrawn in a plastic tube, allowed to clot for at least an hour 
and centrifuged at 2500 rpm for 10 min. Serum was transferred into a 
clean 5 ml plastic tube using a polypropylene pipette and stored at -20  °C.
Post-dialysis samples were obtained with the same procedure from 12 
patients (9 men, 3 women, age 53 ± 21 years, range 23-78, average time 
on dialysis 37 ± 20 months, range 8-67 months).
Blood samples from the TPN subjects were taken using a plastic I.V. 
cannula.
Nickel analysis: Ni determinations were carried out by GFAAS. 
Instrumentation and operative conditions were as described for HAS 
analysis. The graphite furnace programme is reported in Table 2.7. The 
injection volume was 50 pi.
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Table 2.7 Furnace programme for the determination of Ni in 
serum by GFAAS
STEP
TEMP, °C 100
RAMP TIME, s 1
HOLD TIME, s 1
READ
GAS FLOW, ML/MIN 300
150 200 1200 2600
50 30 80 0
5 5 50 4
on
300 300 300* 0
* Gas flow =0 for the last 5 s in this step
6
2700
1
3
300
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Working standard solutions containing 0, 2.5, 5, 10 and 20 pg/L Ni were 
prepared from a Ni stock solution, 1 g/L, ('SpectrosoP, BDH), in HNO3 1% 
v/v.
Aqueous standards and serum samples were diluted 1+1 with a diluent 
solution containing 1% v/v HNO3 and 0.25% v/v Triton X-100. All 
standards and serum samples were analysed in duplicate. Ni 
concentrations in the samples were obtained by comparison with a 
calibration curve obtained from the absorbance of the aqueous standard 
solutions.
Additional analysis: Serum albumin was determined by the bromocresol 
green method with an Olympus automatic analyser.
2.3.2 Results and discussion
Analytical performances o f the method: The plot of absorbance versus 
Ni concentration was linear within the range 0 to 20 pg/L. Using a 
prolonged ashing time, the background signal observed during the 
analysis of serum samples was maintained below 0.150 A s  and 
could be corrected by the deuterium background system. A long ramp 
time was found necessary to avoid the build-up of carbonaceous
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residues. With these conditions, matrix interferences were reduced and a 
calibration graph obtained with aqueous Ni solutions could be used for 
quantitation, but only when absorbance was measured as peak area. The 
plots of peak area versus Ni concentration obtained with either aqueous or 
serum-based standard solutions were parallel (regression lines equations: 
aqueous solutions, y=0.2-10*3 + 7.78-10‘^x, r^=0.998; serum-based 
standards, y=24.9 10*3 + 7.82-10'3x, r^=1.000). No significant difference 
was observed between the concentrations of 38 serum samples, within the 
range 1.5-4.5 pg/L, determined using both aqueous and serum-based 
calibration standards (paired data t-test, average difference -0.06 ±0.13 
pg/L). The peak height signal measured for equal amounts of Ni was 
higher for serum-based standards than for aqueous solutions (regression 
lines equations: aqueous solutions, y=1.3 -10*3 + 6.30-10‘3x, r^=l.000; 
serum-based standards, y=22.7-10"3 + 6.67-10"3x, r^=0.999).
The detection limit, (three times the standard deviation of 10 replicate 
measurements of the blank) was 0.15 pg/L, equivalent to 0.3 pg/L in the 
undiluted sample. The characteristic mass (mass of analyte in pg that 
yields a signal of 0.0044 A s) was 14 pg. Within-day precision was 5.6% 
and between-day precision was 7.5%. The average recovery of known 
amounts of Ni (2.5, 5.0 and 10.0 pg/L) added to a serum sample was 
101 ± 4.8% (n=9).
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The analysis of-Seronorm Trace Element Control Serum (Nycomed AS 
Diagnostics, Oslo, Norway, 3.2 pg/L) and RM 8419, Bovine Serum 
(National Institute of Standards and Technology, Gaithersburg, MT, USA, 
1.8 pg/L) by this method gave average values of 3.21 ±0.17 pg/L (n=10) 
and 0.46 ± 0.05 pg/L (n=4), respectively. A similar discrepancy with the 
certified value of the RM 8419 has been recently reported by two other 
researchers (Andersen et al., 1986; Nixon et al., 1989), who suggested 
that the recommended value of 1.8 pg/L may be in error.
This method compares well with Z-GFAAS procedures, in terms of 
characteristic mass, precision and accuracy (Table 2.8). It shows better 
precision and detection limit than those previously reported for D2-GFAAS 
using older instrumentation (Drazniowsky et al., 1985), although their 
value for the characteristic mass was much lower. On the other hand, the 
detection limit is higher than those reported for procedures that apply 
Zeeman correction. Attempts to improve the sensitivity using a multiple 
injection failed, because of the unmanageable increase in background 
signal.
Therefore, the normal concentrations of Ni in serum of unexposed 
subjects cannot be determined by this method. However, the measurement 
of such low concentrations requires specialised facilities for the control of 
contamination, as described by Nixon et al. (1989), and is
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confined to a limited number of research centres.
Our method, using widely available instrumentation, can be applied by 
less specialised laboratories to monitor Ni exposure, in clinical and 
occupational toxicology.
Nickel concentrations in serum of haemodialysed subjects and controls. 
The concentrations of Ni measured in serum of 25 patients maintained on 
haemodialysis are reported in Table 2.9. The average value was 2.4 + 0.9 
pg/L (range 0.7-4.0 pg/L). In comparison, serum Ni concentrations in 8  
women who were receiving TPN, but had normal renal function, ranged 
between 0.3 and 0.9 pg/L (Table 2.10) and the average value was 0.5 ± 
0.2 pg/L. The distribution of the observed values is shown in Fig. 2.13.
Although the control group could be theoretically exposed to Ni present 
as contaminant in nutrient solutions, Berner et al. (1989) have observed 
that the daily intake of Ni received by patients maintained on TPN is 
comparable with the amounts reported to be absorbed through the 
gastrointestinal tract in healthy subjects. This amount is rapidly eliminated 
by the kidney, provided that the renal function is not affected. The values 
observed for serum Ni concentrations in the TPN subjects are comparable 
with those reported for healthy volunteers (Table 2.11), except Nixon et al. 
(1989). However, because Ni concentrations lower than 0.3 pg/L are not
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Table 2.9 Serum Ni concentrations in haemodialysed patients.
Subject N. Sex Age
(yrs)
Diagnosis
Months
on
dialysis
Serum
Ni
Mg/L
#1 M 78 CRF 48 1.9
#2 M 61 CRF 1 2.6
#3 M 66 CRF-Hypoplastic kidneys 45 1.8
#4 M 22 CRF 26 3.8
#5 F 47 CRF 88 2.8
#6 M 46 CRF 1 0.7
#7 F 61 Mesangiocapillary GN 1 3.6
#8 M 71 CRF 7 1.1
#9 F 71 CRF 73 2.4
#10 F 47 CRF <1 2.0
#11 M 41 CRF 66 2.9
#12 M 55 CRF 27 2.2
#13 M 49 End-stage CRF 290 1.9
#14 M 33 CRF 1 2.8
#15 M 58 CRF 83 2.7
#16 M 62 Crescentis GN 9 1.1
#17 M 39 CRF 49 2.6
#18 M 38 CRF 67 2.0
#19 F 74 CRF 17 1.0
#20 M 77 CRF 36 2.6
#21 M 68 CRF 3 4.0
#22 F 39 CRF 37 3.7
#23 F 23 End-stage RF 23 1.5
#24 M 24 End-stage RF- small kidneys 40 3.7
#25 M 72 CRF 8 2.1
MEAN 53 42 2.4
S.D. 17 57 0.9
MEDIAN 55 27 2.4
CRF=chronic renal failure; GN=glomerulonephritis
77
Table 2.10 Serum Ni concentrations in patients receiving TPN
Subject N. Sex Age (yrs) Serum Ni, pg/L
#1 F 73 0.3
#2 F 69 0.5
#3 F 29 0.9
#4 F 29 0.3
#5 F 30 0.4
#6 F 68 0.5
#7 F 31 0.7
#8 F 56 0.5
MEAN 48 0.5
S.D. 19 0.2
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Table 2.11 Serum Ni concentrations (mean ± s.d., pg/L) in
haemodialysed subjects and controls in earlier studies and 
this investigation.
Reference Controls N Patients N
Hopfer eta I., 1985 0.3 ±0.2 30 5.4 ±2.1 65
Drazniowsky et al., 1985 1.0(0.6-1.4)* 71 7.4(6.0-9.1)* 16
Wills et al.. 1985 0.44 ±0.18 18 3.71 ±1.54 28
Hosokawa et al., 1987 5.6 ± 0.8 30 2.2 ±0.3 30
Hopfer et al., 1989 0.6 ±0.3 22 7.0 ±2.4 30
Nixon et al., 1989 0.14 ±0.09 38 6.38 ±0.18 40
This work, 1993 0.5 ± 0.2 8 2.4 ±0.9 25
* median (lower-upper quartile)
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detectable with this method, the average value of Ni concentrations in the 
control group may be overestimated.
Serum Ni concentration does not appear to correlate with the length of 
dialysis. The average serum Ni concentrations observed in this study for 
subgroups of patients maintained on dialysis for: less than 10 months 
(n=9); 10 to 49 months (n=10); 50 to 88 months (n=5) and 290 months 
(n=1) were 2.2 ± 1.1 pg/L; 2.5 ± 0.9 pg/L; 2.6 ± 0.3 pg/L and 1.9 pg/L, 
respectively. Other researchers (Hopfer et al., 1985; Nixon et al., 1989) 
reported that, in their groups of haemodialysed patients, only those who 
had started the dialysis treatment less than 13 months ago had lower 
serum Ni concentrations compared with the others.
The serum Ni concentrations observed for haemodialysed subjects in 
this study are lower than those reported by other researchers 
(Drazniowsky et al., 1985; Wills et al., 1985; Hopfer et al., 1985; Hopfer et 
al., 1989; Nixon et al., 1989) (Table 2.11). This may reflect the 
improvement of the purity of water and electrolyte concentrate solutions 
now used. The Ni concentration in samples of dialysis fluid, collected just 
before and after the dialyser from 5 dialysis sets, was lower than the 
detection limit of our method (0.45 pg/L for samples diluted 1+2).
Hopfer et al. (1989) observed a significant reduction in serum Ni 
concentrations of a group of haemodialysed patients after six months
81
since the reduction of the Ni content of the dialysis fluid (from 0.82 pg/L to 
0.53 pg/L) due to the introduction of a new reverse osmosis system for the 
purification of the water.
The analysis of serum samples, obtained in the same day from 12 
patients before and after dialysis (Tables 2.12, 2.13), yielded average Ni 
concentrations of 2.2 ± 0.9 pg/L and 3.0 ± 0.9 pg/L, respectively, (p<0.01, 
paired-data t-test). The average increase in serum Ni concentrations after 
a single treatment of dialysis was only slightly lower than those reported by 
Hopfer et al. (1985; 1989) (Table 2.12), despite the lower serum Ni 
concentrations observed in our group of subjects. On the contrary, the 
increment of serum albumin in post-dialysis specimens (pre-dialysis value: 
41 ± 3.5 g/L; post-dialysis value: 45 ± 5.6 g/L; average difference: 
4 ± 5 g/L), due to haemoconcentration, was comparable with the values of 
10% and 8% observed by Hopfer et al. (1985; 1989) (Table 2.13).
Although statistically significant, the Ni increase in our group of 
subjects was very variable and did not correlate with the increment of 
serum albumin or with pre-dialysis serum Ni values. In addition, two 
patients had reduced serum Ni concentrations after dialysis, despite the 
rise of albumin concentrations (Table 2.13). A large variability may also be 
observed in the results reported by Hopfer et al.(1985; 1989) (Table 2.12). 
When individual post - dialysis serum Ni concentrations were corrected for
82
Table 2.12 Serum Ni concentrations (mean ± s.d., |jg/L) in 
haemodialysed subjects before and after a single dialysis 
treatment reported in earlier studies and in this 
investigation.
Reference Pre­
dialysis
Post­
dialysis
Difference N P
Hopfer et al., 1985 6.2 ± 1.8 7.2 ±2.2 1.0 ± 1.1 40 <0.01
3.9 ±2.0 5.2 ±2.5 1.3 ± 1.0 9 <0.01
3.0 ±1.3 3.7 ±1.3 0.7 ±0.3 10 <0.01
Hosokawa et al., 1987 2.2 ±0.3 2.5 ±0.5 0.3 ±0.3 30 <0.01
Hopfer et al., 1989 7.0 ±2.4 8.5 ±2.8 1.5 ±1.3 30 <0.01
This work, 1993 2.2 ±0.9 3.0 ±0.9 0.8 ±0.9 12 <0.01
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haemoconcentration using the serum albumin values, the average 
concentration was 2.7 ± 0.7 pg/L and the increase versus pre-dialysis 
values (mean ± s.d.: 0.5 ± 0.8 pg/L) was lower and not significant by the 
paired-data t-test (Table 2.13).
Despite of the improvement of the purity of dialysis fluids, 
hypernickelaemia, although moderate, still occurred in our group of 
haemodialysed patients. The exchange of Ni 'in vivo' during dialysis 
appears to be variable and depending on factors that have not yet been 
completely clarified.
2.4 CONCLUSIONS
The clinical toxicity of Ni has been considered with regard to two well 
known situations in which adverse effects due to Ni contamination may 
occur: intravenous administration of human albumin solutions and 
haemodialysis. The results of this study showed that the concentration of 
Ni in human albumin solutions has been consistently reduced during the 
past few years and is now largely within limits considered safe. At the 
same time, the serum Ni concentrations of a group of haemodialysed 
patients appear lower than earlier reports suggest. This reduction can be
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attributed to improved purity of the dialysis fluids. However, serum Ni 
concentrations in haemodialysed patients remain elevated in comparison 
with healthy subjects, do not correlate with the length of time since dialysis 
•started and post-dialysis values did not differ significantly from pre-dialysis 
values after correction for haemoconcentration. Although patients do not 
suffer from known adverse effects due to Ni toxicity, the reason why 
patients maintained on dialysis have hypernickelaemia remains unclear. 
The high concentration of contamination of dialysis fluids noted earlier 
may have obscured factors other than dialysis that may also affect serum 
Ni concentrations in subjects with impaired renal function. A better 
understanding of Ni metabolism may prove helpful in identifying some of 
these factors.
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CHAPTER 3
DETERMINATION OF NI ISOTOPES BY INDUCTIVELY 
COUPLED PLASMA-MASS SPECTROMETRY
3.1 INTRODUCTION
Inductively cdupled plasma mass spectrometry (ICP-MS) is a powerful 
technique for the determination of metals, allowing multielemental 
analyses, improved sensitivity for a number of elements and the 
determination of the isotopic composition of the sample.
Instrumentation consists of an inductively coupled plasma torch, placed 
horizontally and interfaced with a quadrupole mass analyser, by means of 
especially designed metallic cones. A system of ion lenses is placed 
behind the cones to form an ion beam, which enters the mass 
spectrometer. Different ions are separated according to their mass/charge 
ratio and can be unequivocally identified. The region between the two 
cones, the ion lenses system and the mass spectrometer are evacuated to 
a low pressure by cryogenic and mechanical pumps. A computerised
87
system provides automatic control of the various functions of the 
instrument, data acquisition and handling. Samples are introduced to the 
torch by pneumatic or ultrasonic nebulisation, generally after a dissolution 
and/or dilution step.
The mass spectra of the elements are considerably simpler than their 
optical emission spectra; however, interferences may arise from 
overlapping of naturally abundant isotopes of different elements and 
polyatomic species formed at high temperature from the carrier gas and 
ions present in the sample. In complex matrices these interferences can 
drastically increase the detection limits and reduce the number of isotopes 
that can actually be used for analytical purposes.
The availability of a relatively simple and rapid technique to obtain 
isotopic information provides the opportunity to apply stable isotopes as 
tracers for the study of mineral metabolism in humans and for accurate 
analytical methods based on isotopic dilution (ID).
Isotope dilution analysis consists of the measurement of isotopic ratios 
in two aliquots of a sample, one of which has been spiked with a known 
amount of an isotope of the element to be determined. The concentration 
of the element in the sample can be calculated from the measured 
isotopic ratios, the amount of the spike and the weight or volume of the 
sample. The uncertainties of the measure of these quantities are the only
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sources of error that can affect the results, since calibration is not needed. 
Losses during the pretreatment of the sample do not modify the isotopic 
ratios. This procedure offers high precision and accuracy and has already 
been applied using thermal ionisation mass spectrometry and spark 
source mass spectrometry for the determination of isotopic ratios. These 
techniques are available to a limited number of laboratories, are more 
time consuming and require more skilful instrument operation and 
complicated sample preparation than ICP-MS.
The establishment of methods of high accuracy based on ID-ICP-MS 
for the determination of trace elements in different biological matrices is 
important for investigations of the roles of trace metals in human health 
and disease, as well as the certification of reference materials and the 
development of reference and routine analytical methods.
Nickel, with five naturally abundant stable isotopes, is an ideal element 
for such experiments. The need for the development of a definitive 
method, based on ID-MS, for the determination of Ni in biological 
materials of human origin, had already been recognised in 1980 by the 
International Union of Pure and Applied Chemistry (IUPAC, 1980b). Since 
then, the only reported attempt to meet this need was a procedure based 
on isotopic dilution-gas chromatography-mass spectrometry, (Aggarwal et 
al., 1989a, 1989b). The Authors determined Ni isotopes in a freeze-dried
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urine reference material (US National Institute of Standards and 
Technology, Standard Reference Material 2670, recommended value 
70 M9/L), after the development of thermally stable, volatile Ni complexes 
with lithium bis(trifluoroethyl)dithiocarbamate.
Inductively coupled plasma mass spectrometry has been applied to the 
determination .of Ni in marine biological reference materials such as 
lobster hepatopancreas (Ridout et al., 1988), dogfish liver and muscle 
tissue (Beauchemin et al., 1988a), cod liver and shellfish tissue 
(Beauchemin et al., 1988b), protein plasma solutions (Diver et al, 1988; 
Lyon et al., 1988a), urine and blood serum (Lyon et al., 1988a; Vaughan 
and Templeton, 1990; Xu et al., 1993). In these studies, the determination 
of all Ni isotopes was affected by a number of isobaric and polyatomic 
interferences (Table 3.1), arising from ions commonly present at much 
higher concentration than Ni in biological samples. In particular, the 
determination of the most abundant Ni isotope (58Ni) is often precluded by 
the overlapping with a minor Fe isotope. Therefore, most of the 
determinations of Ni by ICP-MS were carried out at mass 60, using the 
second most abundant Ni isotope, which was less affected by 
interferences.
In addition, other problems were identified.
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Table 3.1 Possible isobaric and polyatomic interferences affecting the 
determination of Ni isotopes in biological materials by means 
of ICP-MS. (% Natural abundance of isotopes).
ISOTOPE MASS POSSIBLE ISOBARIC AND POLYATOMIC
INTERFERENCES
58Ni (67.76%) 58Fe (0.31%), 42CaO, NaCI
6<>Ni (26.16%) 43CaOH, 42CaO
61Ni (1.25%) « CaOH
62Ni (3.66%) 46CaO, Na2 0 , NaK
64Ni (1.14%) 64Zn (43.9%) 32S02 32S2i 46CaO
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Ridout et al. (1988) observed lower Ni values than expected in digested 
lobster tissue and attributed this discrepancy to signal suppression from 
high total dissolved solid content.
Beauchemin et al. (1988a, 1988b) reported significant interferences, 
due to Ca oxides and hydroxides, at mass 60 and 61, with the result that 
neither the 61/60 nor the 62/60 isotope pairs could be used for the 
determination of Ni by the ID technique in marine reference materials. 
However, the results provided by the standard addition method on 58Ni 
(Beauchemin et al, 1988a) or external calibration using 60Ni (Beauchemin 
et al., 1988b) were in good agreement with those obtained in 
interlaboratory comparisons with various other techniques.
Diver et al. (1988) and Lyon et al. (1988a) observed reasonable 
agreement between the values obtained by ICP-MS using 60Ni and those 
provided by GFAAS and ICP-AES in freeze-dried plasma protein solutions 
with high Ni content (>0.4 mg/L), whereas the results obtained for the 
analysis of all the elements of the first transition row, including Ni, in 
commercial freeze-dried control urine were severely degraded by 
polyatomic interferences (Lyon et al., 1988a).
Besides interferences from Ca oxides and hydroxides at mass 60 and 
61, Lyon and Fell (1990) identified as Na20  a peak at mass 62 observed 
in diluted serum samples. Vaughan and Templeton (1990) reported
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spectral overlaps, attributed to the species NaK and Na20, with 62Ni in 
samples of urine. These Authors used a mathematical treatment (principal 
component analysis, PCA) to separate the information from the analyte 
and the overlapping species and were able to determine Ni in a freeze- 
dried urine reference material (NIST SRM 2670), after a 40% dilution with 
water. The major problem encountered using mathematical correction of 
interferences was the unpredictable variability of the species formed, 
which was not linear with time and also depended on the number and salt 
content of the analysed samples. Therefore, reference solutions of Ca and 
Na had to be run frequently to compensate for the drift, the most recent 
data being used for calculations. In a later paper, Xu, Stuhne-Sekalec and 
Templeton (1993) applied PCA to the determination of Ni in digested 
serum, but preferred to reduce the Ca content in urine samples by 
precipitation as Ca oxalate, since mathematical treatment was not robust 
enough for routine analysis of Ni concentrations in urine (1-5 pg/L Ni).
The determination of Ni isotopes in other human biological materials, 
such as red cells and faeces, which are important for metabolic studies, 
have not yet been reported.
I investigated the use of separation techniques to eliminate the ions 
causing interferences on the determination of Ni isotopes in biological 
materials. Using size-exclusion chromatography (SEC), I reduced the
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sodium content of human albumin solutions and established an ID-MS 
procedure for Ni analysis. Since SEC was not suitable for other biological 
materials and lower Ni concentrations, I investigated a more efficient 
procedure of purification, based on complex formation and solvent 
extraction. This method of separation had already been successfully used 
as part of the reference method proposed in 1980 by the IUPAC 
Toxicology Committee for the analysis of Ni in serum and urine by GFAAS 
(IUPAC, 1980b). I applied the same procedure, modified to allow for 
higher sample volume and standardisation with ID, to the determination of 
Ni isotopes by ICP-MS. Preliminary results were obtained on samples of 
human plasma, red cells, urine and faeces, spiked with 62Ni and 61 Ni, to 
assess the feasibility of an accurate study of Ni absorption, distribution 
and excretion in man, using 62Ni as a metabolic tracer and 61 Ni for ID.
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3. 2 SIZE-EXCLUSION CHROMATOGRAPHY FOR THE REMOVAL OF 
INTERFERENCES IN THE DETERMINATION OF NI IN HUMAN 
ALBUMIN SOLUTIONS BY MEANS OF ID-ICP-MS
Size-exclusion chromatography (SEC) is used to separate biological 
molecules according to their size and to substitute unwanted ions and low 
molecular weight compounds in complex solutions with suitable buffers.
Since many of essential trace metals are strongly bound to proteins, 
the metal-protein complex can be separated by SEC from ions known to 
cause polyatomic or isobaric interferences.
Lyon et al. (1988b) used SEC to remove chloride ions from blood 
serum and eliminate a major interference (40Ar37CI+), affecting the 
determination of 77Se. In a later paper, Lyon and Fell (1990) applied the 
same procedure to the determination of the isotopic composition of Cu in 
blood serum by ICP-MS. Copper analysis in serum suffered from the 
overlapping of the major Cu isotope, 63Cu, with the polyatomic species 
23Na40Ar. This was completely eliminated after reduction of the sodium 
content by SEC.
The same approach could be used for the determination of other metals 
with known high affinity for specific proteins, such as Ni has for albumin 
(stability constant of the 1:1 Ni2+-albumin complex: 109-57 litres/mole,
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Glennon and Sarkar, 1982). Most of the interferences in Ni analysis by 
ICP-MS are caused by the high Na and Ca content, which can be reduced 
by SEC. However, the proportion of serum Ni bound to proteins and that 
in low molecular fractions has not been definitely established and may 
vary between individuals. Therefore, ID would be required to provide 
quantitative results for total Ni content of the sample and allow for any 
incomplete recovery. This requires that at least two isotopes are made 
available for determination.
I investigated the use of this technique for the analysis of Ni in human 
albumin and plasma protein solutions (HAS, PPS), which are available in 
large amounts and contain higher concentrations of Ni than human serum 
or plasma, due to contamination during the production process (Diver et 
al., 1988; ch. 2).
3.2.1 Experimental
Instrumentation: Measurements of isotopic ratios and quantitative 
determinations of Ni were carried out on a PlasmaQuad inductively 
coupled plasma mass spectrometer (VG Elemental, Cheshire, UK). 
Instrumental settings and operating conditions are reported in Table 3.2.
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Table 3.2 ICP-MS operating conditions.
Plasma
R.f. power
Gas control
Nebulizer
Ion sampling
Vacuum
Data aquisition:
Forward 1.3 kW
Reflected <10 W
Auxiliary 0.6-0.7 l/min
Coolant 13-14 l/min
Nebulizer 0.75-0.85 l/min
Meinhard type pumped at 0.7 ml/min
Spray chamber Scott-type double bypass,
water cooled
Sampling cone
Skimmer cone
Sampling distance
Nickel sampler (Nicone) with 
1.0 mm orifice
Nickel (001 Type) with 0.75 
mm orifice
10 mm from load coil
Expansion stage 2.4 mbar 
Intermediate <1x10_4mbar
Analyser 3 x 10-6 - 4 x 10-6 mbar
Peak jumping 
No. channels 1024
No. of sweeps 20
Points per peak 5
Dwell time 80 ps
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Reagents: 62Ni, 98.83%, was purchased from AEA Technology, Oxford, 
UK. The mass analysis is shown in Table 3.3. Solutions of naturally 
abundant Ni were prepared from a stock standard solution of Ni 1000 
mg/L in HNO3 M (BDH, 'Spectrosol', BDH Ltd., Poole, UK). Disposable 
chromatographic columns, pre-packed with Sephadex G-25 M, (PD-10), 
were from Pharmacia LKB Biotechnology (Stockholm, Sweden). Nitric acid 
65%, (Aristar, BDH) was further purified by subboiling in PTFE bottles. 
Ultrapure water was obtained by a four-stage purification using ion- 
exchange (Elgastat UHP, Elga, High Wycombe, UK).
Samples: Samples of HAS and PPS were obtained from the GRI 
Pharmacy or donated by manufacturers (Sec. 2.2).
Spiking procedure: Seven mg of 62Ni were dissolved in 1 ml of 
concentrated HNO3 and made up to 100 ml. Spiking solutions containing 
0.7 mg/L and 7 mg/L of 62Ni were obtained by appropriate dilution in 1% 
HNO3 . A volume of 15 ml of each protein solution was spiked with an 
appropriate amount of 62Ni, chosen to obtain a 62/60 ratio in the sample 
close to 1. The spiking solutions were calibrated by reverse ID. 
Calibration solutions contained 100 pg/L of naturally abundant Ni and 
approximately 28 pg/L of 62Ni.
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Table 3.3 Mass analysis of enriched isotope preparations, as provided 
by manufacturer.
____________________________________ Atom %_______
Enriched isotope 58 60 61 62
62Ni 0.32 0.63 0.13 98.83
61NiO 1.93 3.41 93.61 1.06
64
0.09
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Size-exclusion chromatography. To remove any Ni contamination, all 
PD-10 columns were washed with 20 ml of Na2 EDTA 69 pmol/L and 
rinsed with 30 ml of de-ionised water before use. A volume of 2.5 ml of 
each spiked albumin solution was loaded onto the column and eluted with 
3.5 ml of de-ionised water. Samples were stored at +4°C until analysis 
and then further diluted with 1% HNO3 to a final dilution of 1:10.
ICP-M S analysis:
Isotopic dilution analysis: Five measurements were carried out on each 
sample. The background signal obtained by analysing a blank solution 
(subboiled HNO3 1%) was subtracted to all other measurements. The 
extent of mass discrimination affecting the measurement of the isotopic 
ratio 62/60 was evaluated at the beginning of every day by running a set 
of solutions of naturally abundant Ni and checked periodically during the 
day, running a standard solution every 5 samples.
The measured ratio (IR) between the spiked (A) and the reference (B) 
isotope in a sample corresponds to :
IR = (An + As) / (Bn + Bs) 
where An and Bn are the masses of the spike and the reference isotopes 
in the sample before spiking and Ag and Bs are the masses of the spike
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and the reference isotopes in the spike solution. From this equation the 
following formula was derived to calculate the concentration of Ni in the 
sample:
Ms (As-Bs IR) W
C = ----------------------------
As (IR B-A) V
where C is the analyte concentration in the sample (pg/L or pg/g), Ms is 
the mass of the spike isotope (nmol), V is the volume (ml) or weight (mg) 
of the sample, A is the natural abundance of the spike isotope, B is the 
natural abundance of the reference isotope, As is the abundance of the 
spike isotope in the spike, Bs is the abundance of the reference isotope in 
the spike, W is the atomic weight of the element to be determined and IR 
is the measured ratio (spike isotope/reference isotope) corrected for mass 
discrimination where needed, after the spike addition.
The concentration of the spike solution was determined by reverse 
calibration and calculated according to:
(IR B - A) Q
c s= -----------------------------
(1 -IR Bs / As) Vs
where Cs is the concentration of the spike solution, Q is the amount of 
total Ni present (nmol), Vs is the volume of the spike (mL).
External calibration: Human albumin solutions were diluted 1:5 or 1:10
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in HNO3 1% and spiked with 50 pg/L In as internal standard. Three 
measurements were carried out on each sample and a blank solution (1% 
HNO3 ) was subtracted to each measurement as described above. A set of 
standard Ni solutions prepared in HNO3 1% was also analysed and the 
calibration curve and samples concentration were obtained using the 
instrument software.
3.2.2 Results and discussion
Preliminary analyses were carried out by quantitative ICP-MS using 
external calibration on HAS with a range of Ni concentrations, simply 
diluted 1:5 (Table 3.4). As expected, only the results obtained at mass 60 
were in good agreement with results provided by GFAAS for all samples. 
The concentrations measured at mass 62 were highly degraded by the 
presence of polyatomic interferences, but in one sample, desalted on a 
PD-10 column before analysis, results were in close agreement with the 
concentration measured at mass 60 and by GFAAS.
These findings suggested that the desalting procedure could make the 
62Ni isotope available for ID. The results obtained for HAS with Ni content 
higher than 50 pg/L by means of three different techniques: ICP-MS with 
external calibration, ID-ICP-MS and GFAAS are compared in Table 3.5.
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Table 3.4 Nickel concentrations determined at various masses in HAS 
diluted 1:5 by ICP-MS using external calibration. Sample 
LD1 was also desalted on a PD-10 column.
ICP-MS GFAAS
Mass: 58 60 61 62
Sample: 
A, pg/L 27 21 12 4575 20.4
B, pg/L 12 8 12 10855 7.4
H, pg/L 107 95 139 11200 98
F, pg/L 74 66 85 7200 65
HMS, mg/L 0.39 0.36 0.43 8.5 0.39
E, mg/L 0.38 0.36 0.42 7.9 0.37
A1, mg/L 0.44 0.43 0.48 8.9 0.43
LD1, pg/L 70 65 80 67 64
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Table 3.5 Comparison of different procedures for the determination of 
Ni in HAS: ICP-MS with external calibration; ID-ICP-MS and 
GFAAS (Ni concentrations > 50 pg/L, standard deviation in 
enclosure).
SAMPLE ICP-MS* ID-ICP-MS^ GFAAS
CODE 60Ni
KAG, pg/L 52 (2 .0 ) 51 (1.6 ) 64
F. M9/L 66 (1.5) 64 (2 .0 ) 65
H, pg/L 95 (1.5) 93 (1.4) 98
A1, mg/L 0.441 (0.003) 0.424 (0 .002) 0.43
SHA1, mg/L 1.03 (0 .02) 1.10 (0.003) 1.02
* dilution 1:10
# SEC and dilution 1:10
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The isotopic ratio was measured with a precision ranging from 3.3 to 
0.3%, for Ni concentrations between 51 and 1100 pg/L. The results 
obtained with the three methods were in good agreement, confirming that 
SEC was effective in reducing the concentration of interfering species. 
However, sensitivity was insufficient to determine accurately Ni 
concentrations below 50 pg/L.
I attempted the direct determination of Ni concentrations lower than 50 
pg/L in desalted samples of HAS and human serum, after protein 
precipitation with concentrated HNO3 . The Ni content in these samples 
was calculated for both 60Ni and 62Ni using external calibration and 
compared with results obtained by GFAAS (Table 3.6). The 
concentrations of Ni determined at mass 60 were still in agreement with 
the GFAAS results or the expected values, although generally lower, but 
definitely unreliable results were obtained from the 62Ni isotope, indicating 
unresolved interferences and precluding ID.
The high results reported for 62Ni in Table 3.6 could be due to poor 
resolution between a rather small 62Ni signal and a quite large 63Cu peak. 
The 63Cu isotope accounts for 69% of the Cu concentration, which in HAS 
ranged from 64 to 239 pg/L, (ch. 2, Table 2.5) and in human serum from 
500 to 1500 pg/L. Beauchemin et al. (1988a) also reported the 
overlapping between the 63Cu and the 62Ni peak in the analysis of two
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Table 3.6 Determination of Ni at mass 60 and 62 by ICP-MS in: HAS, 
compared with values obtained by GFAAS; human serum 
samples, spiked with known amounts of Ni (Ni 
concentrations < 50 pg/L, standard deviation in enclosure). 
Sodium content of the samples, determined by Flame Atomic 
Emission Spectrometry.
SAMPLE ICP-MS* GFAAS Na
CODE 60Ni 62Ni
mq/l mq/l mq/l mmoL
12 6.9 (0.2) 89 (50) 7.7 2.9
14 8.0 (0.3) 321 (90) 8.5 3.0
1 9.3 (0.4) 485 (82) 13.5 2.4
L 11 .0 (0 .1) 632 (99) 13.6 2.8
A 21.0 (0 .1) 539 (62) 20.4 2.2
HS** 4.1 (0.2) 1101 (103) 4.7
HS + 25 pg/L 25.1 (0.4) 870 (125) 4.2
HS + 50 pg/L 44.7(1.2) 786 (121) 4.3
* SEC and deproteinization
** Human serum
marine reference materials with Cu/Ni ratios of 5 and 80, respectively, and 
aqueous solutions with comparable concentrations of Cu and Ni. This 
interference could only be removed by operating at an higher resolution 
level (Beauchemin et al., 1988a; 1988b).
Another possible cause of these abnormal results could be the 
presence of residual interferences from Na2 0  and NaK species. The Na 
content of the samples presented to ICP-MS ranged from 2.2 to 3.0 
mmol/L in HAS and from 4.2 to 4.7 mmol/L in serum samples (Table 3.6). 
Attempts to further reduce the Na content in the desalted fraction of serum 
samples by repeated runs on the PD-10 columns were not successful 
(Table 3.7). The concentration of Na in the eluate after 4 consecutive runs 
was only slightly reduced in comparison with that obtained after a single 
run (10.7 mmol/L). Therefore, I studied the elution profile of Na from the 
PD-10 columns and investigated some procedures for the complete 
elimination of Na ions from the samples.
In this experiment, I loaded a PD-10 column with 2.5 ml of human 
serum, followed by 12.5 ml of water. One ml fractions of the eluate were 
collected, starting as soon as the sample was loaded onto the column. 
Sodium content was determined in each fraction by flame atomic emission 
spectrometry (FAES) and the protein elution was monitored by 
determining the UV absorbance of each fraction at 285 nm. The elution
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Table 3.7 Sodium content (standard deviation) in desalted serum 
fractions after repeated runs on PD-10 columns, corrected 
for dilution factor.
Na, mmol/L 
Run Column A_______Column B
1 10.7(0.90) 10.7(0.05)
2 10.1(0.05) 9.3(0.10)
3 9.4 (0.50) 8.9 (0.40)
4 7.7(0.10) 8.1 (0.25)
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profile of Na and total protein are shown in Fig. 3.1. The two major peaks 
of Na and protein are well resolved, but small amounts of Na are eluted 
together with the proteins. The same experiment was then performed 
loading the column with 2.5 ml of a desalted serum fraction, obtained by 
running the same serum on a PD-10 column according to the procedure 
reported in Sec. 3.2.1. This second experiment indicated that the minor 
peak of Na was still eluted together with proteins and was identical to that 
observed in the first experiment (Fig. 3.1). I concluded that the residual 
fraction of Na could not be separated by SEC because of its association 
with proteins. Fogh-Andersen et al. (1993) studied the bound and net 
charge of human serum albumin at pH values between 4 and 9 and 
reported a -20 net charge per albumin molecule at pH=7, which could 
explain the electrostatic association of positive ions. Sodium ions 
associated with proteins could be partially substituted with alternative ions. 
In two separate experiments I added KCI or RbN0 3  (133 mmol/L) to a 
desalted serum sample and left it to equilibrate overnight at room 
temperature in the first case and for two hours on a rotating mixer in the 
second occasion. The samples were then run again through a PD-10 
column and the eluate fractions were collected and analysed as described 
above. The elution profiles of Na were almost identical in both cases 
(Fig. 3.2). I observed a net reduction of the amount of Na eluted between
109
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2 and 6 ml, as a consequence of the exchange of positive ions. I 
estimated the Na fraction still eluted together with the proteins as 2.1% 
and 2.5% of the initial Na content of the serum sample, for K and Rb 
incubation, respectively. In comparison, 8.4% of the initial Na content was 
eluted between 2 and 6 ml from non incubated serum samples. For a 
starting material with a Na concentration of 140 mmol/L, pre-incubation 
with competitive ions could reduce the Na concentration in the final 
solution to 1.4-1.7 mmol/L, taking into account a dilution factor of 2.058 for 
desalting and deproteinisation. According to results reported in Table 3.6, 
this concentration might still cause an interference at mass 62. In addition, 
high concentrations of salts and total dissolved solids caused problems 
when the samples were analysed by ICP-MS. A dilution of at least 1:10 of 
the samples was needed to avoid increasing imprecision and possible 
blockages due to salt deposits on the inner parts of the instrument.
In conclusion, although SEC proved valuable for the analysis of HAS 
with high Ni content, this method was limited by poor sensitivity and can 
suffer from residual interferences.
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3.3 DETERMINATION OF Nl ISOTOPES IN BIOLOGICAL MATERIALS 
BY ID-ICP-MS AFTER SOLVENT EXTRACTION
Solvent extraction has been widely used for the separation and 
preconcentration of metals from biological and environmental matrices. 
The procedure described in 1980 by the IUPAC Committee on Ni 
Toxicology (IUPAC, 1980), as part of the recommended method for the 
determination of Ni in biological fluids by GFAAS, has been accurately 
tested in an international trial and could be easily adapted to the 
treatment of solid samples as well. The complete removal of Na and Ca 
provided at least three Ni isotopes free from interferences and both in vivo 
enrichment and ID could be performed using the two minor isotopes.
3.3.1 Experimental
Samples: Analyses were carried out on human serum, plasma, red 
cells, urine and faeces specimens obtained from healthy volunteers and 
spiked with naturally abundant and enriched Ni. Red cells were separated 
from plasma by centrifugation at 2500 rpm for 15 min, washed three times 
with saline solution (0.9% NaCI, 'Arista^ grade, 99.99%) and lysed by 
addition of a volume of de-ionised water equal to the plasma volume.
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Faeces were collected in a weighed plastic tub and homogenised after 
addition of a known amount of water. A 50 ml aliquot was weighed into a 
glass round bottom flask, freeze-dried and ground to a fine powder.
Nickel determination was also performed in the following control 
materials: Seronorm Trace Elements Urine batch no. 009024 (Nycomed 
Pharma, Oslo), recommended value 40 pg/L of Ni (range 36.4-42.8); BCR 
CRM 185, Bovine Liver and BCR CRM 186, Pig Kidney (Commission of 
the European Communities, Community Bureau of Reference, Brussels, 
Belgium), indicative Ni content 1.4 pg/g and 0.42 pg/g, respectively.
Instrumentation: All measurements were carried out on a PlasmaQuad 
SX300 inductively coupled plasma mass spectrometer (VG Elemental, 
Winsford, Cheshire, UK) at the Rowett Research Institute, Aberdeen, 
Scotland. Samples were introduced by means of a peristaltic pump, using 
a Meinhard nebulizer. Instrumental settings and operating conditions were 
as reported in Table 3.2.
Reagents: Stable nickel isotopes, 61 Ni (93.61%, as NiO) and 62Ni 
(98.83%, as metal) were obtained from AEA Technology, Oxford, UK. 
Mass analyses for both enriched materials were as reported in Table 3.3.
Ultrapure acids (HN03, 70%, HCI04, 70% and H2S04. 98%, 'Aristar'
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grade;) methylisobutylketone (MIBK), 99.0%, ammonium tetramethylene- 
dithiocarbamate (ammonium pyrrolidine dithiocarbammate, APDC) 99.0%, 
and a Ni stock standard solution 1 g/L, all 'Spectrosol* grade, were from 
BDH Ltd. (Poole, UK). Nitric acid was further purified by subboiling in 
PTFE bottles. Ultrapure ammonia (NH4 OH, 25%) was from Normatom, 
ProLabo, France.
Potassium dihydrogen orthophosphate anhydrous (KH2 PO4 ), 99.0%, 
disodium hydrogen orthophosphate (Na2 HP0 4 >, 99.5%, bromothymol 
blue (BTB) and chloroform (CHCI3 ), all 'Analar' grade, were also from 
BDH.
Ultrapure water was obtained by a four-stage purification using ion- 
exchange (Elgastat UHP, Elga, High Wycombe, UK).
Working solutions: All working solutions were prepared according to the 
recommended IUPAC procedure (IUPAC, 1980). These included the acid 
mixture used for the digestion of samples, containing 3 parts of HN0 3 , 1 
part of HCIO4 ancl 1 Part ° f H2 SO4 ; so*ut>ons of BTB (0.4 g/L); APDC 
(2%), freshly prepared and purified by repeated extraction with MIBK; 
diluted NH4 OH (5%); diluted HNO3 (1%) and a phosphate buffer 
containing 0.5 mol/L of KH2PO4 and 0.5 mol/L of Na2 HP0 4 , pH=7, 
purified by extraction with APDC/CHCI3 .
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Preparation and calibration of the 61 Ni and 62Ni spike solutions. Stock 
solutions of 61 Ni (approximately 50 mg/L) and 62Ni (approximately 70 
mg/L) were prepared by dissolution of appropriate amount of materials in 
concentrated acid. Five mg of 61 Ni as*61NiO were dissolved with 4 ml of 
HNO3 and HCI 1+1 and the solution made up to 100 ml. The preparation 
of the 62Ni solution was described in sec. 3.2.1. The actual concentration 
of the 61 Ni and 62Ni spike solutions was determined by ICP-MS using a 
reverse calibration procedure (sec. 3.2.1).
Contamination control: To avoid inadvertent contamination of 
specimens, all glass- and plastic-ware was soaked overnight in nitric acid 
2 0 %, rinsed in ultrapure water and dried in a laminar flow hood. 
Manipulation of samples was also carried out in a laminar flow hood. 
Automatic pipette tips were rinsed three times with 20% nitric acid and 
ultrapure water before use.
Procedure: All samples were completely mineralised by acid-digestion. 
After addition of APDC, the Ni-complex was extracted in MIBK. The 
organic extracts were evaporated and the residues dissolved in 
concentrated HNO3 then diluted to appropriate volume prior to analysis 
by ICP-MS. Stable isotopes for ID were added before digestion.
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Acid-digestion: Five ml of water (blank), Ni standard solution, serum, 
plasma, red cells or urine and weighed amounts (0.2-0.5 g) of the solid 
samples (lyophilised faeces and tissues) were placed in 50 ml Pyrex 
conical flasks. Five ml of ultrapure water were added to solid samples.
For ID, appropriate amounts of the isotope solution were added to the 
samples at this stage and they were left to equilibrate for at least two 
hours at room temperature. The amount of isotope added was calculated 
to result in a ratio close to 1 for the chosen isotope pair.
Five ml of the acid mixture were added to each sample, the flasks 
covered and left overnight. The following day, the flasks were placed on a 
hot plate and digested according to the following temperature program: 
110°C for 1 hr, 150°C for 2 hr, 200°C for 1 hr, 230°C for 30 min, 260°C for 
30 min, 300°C until digestion was completed (about 2.5 hr). At this stage, 
the samples were clear, residual volume was about 1.5 mL and little or no 
more fumes were present. The samples were then left to cool down 
overnight in the laminar flow hood.
APDC/MIBK extraction: The pH range for the extraction of APDC-metal 
chelates has been widely investigated. Ni complexes were quantitatively 
extracted from aqueous solutions with pH values between 1 and 10 
(Watson, 1971).
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However, the IUPAC Committee observed poor stability of Ni 
complexes in the organic phase at low pH value and recommended the 
extraction to be carried out at pH=7 (IUPAC 1980). To adjust the pH of the 
digests to 7, I added to each sample: seven drops of BTB, 7.5 mL of 
ultrapure water, 3 mL of 25% NH4OH and five drops of phosphate buffer. 
Addition of dilute (5%) NH4 OH continued until the colour of the solution 
changed from yellow to a green-blue shade comparable to that of an 
aqueous solution at pH=7 containing the same amount of BTB and 
phosphate buffer.
After addition of 1.25 mL of 2% APDC, each flask was mixed for 1 min 
and all samples were left standing for 15 min. Two mL of MIBK were 
added to each sample. Each flask was mixed by swirling for 2 min, then 
the content was poured in a 15 mL Pyrex glass tube. The organic phase 
separated without centrifugation and was transferred to a clean Pyrex 
glass tube. When external calibration was used, an exact volume of the 
organic phase (1.5-1.8 mL) was transferred.
Evaporation and dissolution: The organic extracts were evaporated to 
dryness using a heating block which was set at 120° C for 30 min and at 
150°C for 45 min. The glass tubes were wrapped in Al foil to facilitate heat 
diffusion and shielded to reduce heat loss and avoid contamination.
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Once dried, the extracts were left to cool at room temperature, then 
completely dissolved in 0.25 mL of HNO3 followed by 0.75 mL of ultrapure 
water and well mixed to ensure complete dissolution. The samples were 
finally diluted with 8 mL of ultrapure water, mixed by inversion several 
times and stored at room temperature until analysis.
Analysis: A blank solution (2.8% HNO3 , corresponding to the acid 
concentration in the diluted extracts) was subtracted from all sample 
measurements to eliminate contributions from the background. The 
analyte concentration was calculated as described in section 3.2.1.
For quantitative analysis using external calibration, a set of Ni standard 
solutions prepared in HNO3 2.8% was analysed together with the digests 
and a calibration curve and samples concentrations were obtained using 
the instrument software.
3.3.2 Results and discussion
Analytical performance: The mass spectra of a standard Ni solution, 
compared with extracted blank, urine and faeces samples, are shown in 
Fig. 3.3, 3.4, 3.5 and 3.6.
To assess the absence of interferences at the selected masses, the
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Fig. 3.3 Mass spectrum of blank (digested and extracted).
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Fig. 3.4 Mass spectrum of human urine spiked with 50 pg/l Ni (digested 
and extracted).
40 7042
Fig. 3.5 Mass spectrum of human serum spiked with 50 pg/l Ni (digested 
and extracted).
0135
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Fig. 3.6 Mass spectrum of human faeces (digested and extracted).
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natural isotopic ratios between couples of isotopes were determined in 
various unspiked biological matrices (Table 3.8). The results obtained for 
urine, serum and faeces agreed well with the expected values for all the 
considered isotope pairs, within the limits of the experimental procedure, 
although a residual interference at mass 58 for serum samples was 
suspected. Due to the low natural abundance of 61 Ni, 61/58 and 61/60 
ratios were only determined in faecal samples, which had a high Ni 
content. The analysis of lyophilised Pig Kidney provided good results for 
the isotopic ratio 62/60 but definitely lower values for the 62/58 and 60/58 
ratios. Since Fe, Cu and Zn complexes with APDC are also extracted by 
this procedure, 58Ni may suffer from overlapping with 58Fe in samples with 
high Fe content, such as tissues (Fe concentration in CRM Pig Kidney: 
299 M9/9)- The 64Ni isotope, with a natural abundance of only 1.14%, is 
almost always overwhelmed by the much more abundant 64Zn in 
biological samples and was not considered in this study. A residual 
interference of 63Cu on 62Ni may also occur in samples with unfavourable 
Cu/Ni ratio. Beauchemin et al (1988a) observed this effect in samples of 
marine biological reference materials, which Ni/Cu ratio was 1:5 and 1:80, 
respectively. In this study, I only occasionally observed an overlap 
between the tail of the 63Cu signal and the 62Ni peak in serum samples 
with very low Ni concentration and standard solutions with similar Cu/Ni
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Table 3.8 Isotopic ratios between different couples of Ni isotopes 
measured in unspiked biological samples after digestion and 
APDC/MIBK extraction. (All measurements corrected for 
mass bias; standard deviation in enclosure).
Isotopic ratio 
62/58 62/60 61/58 61/60 60/58
Expected ratio
Sample N
0.0540 0.1399 0.0184 0.0478 0.3861
Seronorm Urine 1 0.0534 0.01389 - - 0.3844
(0.0006) (0.0035) - (0.0062)
Serum 1 0.0519 0.1394 - - 0.3729
(0.0016) (0.0076) - - (0.0104)
Pig kidney 1 0.0376 0.1405 - - 0.2677
(0.0004) (0.0043) - - (0.0053)
Faeces 5a 0.0556 0.1427 0.0188 0.0483 0.3891
(0 .0012) (0.0016) (0.0005) (0.0015) (0.0061)
a mean value from 5 different samples
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concentrations (500/2.5). The 62/60 ratio was not affected in the Pig 
Kidney, which had a Cu concentration of 31.9 |jg/g.
The results obtained for Ni added to various biological samples and 
reference materials, by means of ID with 62Ni and ICP-MS (Table 3.9) 
indicated a satisfactory recovery from both serum (98 and 99.2%) and 
urine samples (98.5% and 103%) when the ratio 62/60 was used for 
calculation. Serum Ni values derived from the 62/58 ratio were slightly 
higher than expected (113% and 106%) which may be due to a residual 
Fe interference, whereas urine results agreed well with those derived from 
the 62/60 ratio (98% and 101%).
The analysis of Seronorm urine yielded values within the range of 
expected concentrations, although slightly higher than the target value 
(Table 3.9). However, as the manufacturer states that the control urine is 
prepared from normal urine spiked with 40 pg/L of Ni, a value slightly 
higher than 40 pg/L may be more accurate.
The determination of Ni in the reference material Pig Kidney gave very 
different values for the two isotopic ratios considered (Table 3.9). The 
result obtained from the isotopic ratio 62/58 was much higher than the 
indicated value. This was expected, since the analysis of unspiked 
materials (Table 3.8) suggested a possible overlap with 58Fe. The result 
obtained from the 62/60 ratio is closer to the indicated value, although the
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Table 3.9 Determinations of Ni in water, serum and urine spiked with 
natural Ni, using isotopic dilution with 62Ni (pg/L ± RSD%).
MATRIX ADDED
Ni
Ni ISOTOPE 
62/58
RATIOS
62/60
WATER 25 25.6±2.5 25.2±2.7
25 25.0±3.9 24.6±2.2
WATER 50 50.2±0.7 49.9±1.9
50 48.8±2.7 48.5±2.2
SERUM (0.3 pg/L) 25 28.2±1.8 24.5±2.0
50 52.8±1.9 49.6±3.1
URINE (2.0 pg/L) 25 27.4±2.5 27.9±2.1
25 26.5±1.4 26.6±3.7
SERONORM URINE 40a 42.4±3.2 41.4±2.1
40a 41.9±2.7 42.8±4.1
RM PIG KIDNEY 0.42b 1.08±1.3 0.61±1.4
RM BOVINE LIVER 1.4b 2.53±1.3 2.01±0.9
a Recommended value, range 36.4-42.8 pg/L. 
b Indicative value, pg/g
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difference still amounts to 0.19 pg/g (37%). The origin of this discrepancy 
is not clear, since the 62/60 ratio determined in unspiked Pig Kidney was 
in good agreement with the theoretical values, thus suggesting freedom 
from interferences. Since this material has not been certified for its Ni 
content yet, further analyses may be needed to gain some definite 
information. The analysis of the reference material Bovine Liver gave 
higher than expected isotopic ratios for both isotope pairs, which were 
attributed to high Fe and Cu content (214 and 189 pg/g, respectively).
The results of determinations performed on the same materials using 
external calibration are reported in Table 3.10. Ni was determined at mass 
58, 60 and 62. The isotope 61 Ni, natural abundance 1.25%, did not 
provide a large enough signal. The determinations obtained at the various 
masses are in good agreement, but results were much lower than 
expected. I concluded that the sample pretreatment needed to remove 
interfering ions may lead to losses of material, during the digestion and/or 
extraction steps, and reckoned ID as mandatory for accurate results. The 
analysis of the lyophilised Pig Kidney gave higher results than expected.
Within run precision of ID-ICP-MS analysis of Seronorm urine was 
1.4% and 1.7% (n=4), for the isotopic ratios 62/58 and 62/60, respectively. 
For serum samples, the coefficient of variation was 5.4% for the isotopic 
ratios 62/58 and 2% for the ratio 62/60, respectively (n=4, Table 3.11).
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Table 3.10 Results of the determinations of Ni in water, serum and 
urine, spiked with natural Ni, using external calibration 
(pg/L ± RSD%).
MATRIX ADDED
Ni
Ni ISOTOPES
58 60 62
WATER 50 41,0±3.3 41.7±2.1 38.0±3.2
46.3±1.1 46.0±2.9 44.1±1.5
38.0±0.5 38.0±1.6 30.4±9.9
SERUM (0.3 pg/L) 50 50.0±2.8 49.5±3.1 46.0±5.6
55.7±1.1 52.3±0.8 50.5±3.1
46.8±0.4 45.8±3.1 43.6±4.6
URINE (2.0 pg/L) 50 51.6±2.6 51.1 ±3.6 46.3±4.4
48.3±1.4 47.1±2.3 44.9±8.8
SERONORM URINE 408 30.8±1.3 31.2±3.2 29.0±1.4
RM PIG KIDNEY 0.42b 1.18±2.0 0.82±3.9 0.80±1.6
a Recommended Value, Range 36.4-42.8 pg/L. 
b Indicative Value, pg/g
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Table 3.11 Replicate determinations of Ni by means of ID-ICP-MS with 
62Ni in control urine and human serum. Nickel concentration 
derived from both 62/58 and 62/60 isotopic ratio.
MATRIX TARGET VALUE
M y .
Ni CONCENTRATION 
(pg/L ± SD) 
62/58 62/60
SERONORM URINE 
1st Replicate 
2nd Replicate 
3rd Replicate 
4th Replicate 
OVERALL MEAN 1 SD
40.0 (36.4-42.8)*
42.9±0.9
41.4±0.2
41.7±0.3
41.6±0.5
41.9±0.6
42.711.0 
40.710.2 
41.611.4
41.411.1 
41.610.7
SERUM
1st Replicate 
2nd Replicate 
3rd Replicate 
4th Replicate 
OVERALL MEAN 1 SD
20.0
21.810.8
20.610.7
23.310.2 
23.410.6
22.311.2
19.610.5
19.110.5
20.210.6 
19.710.5 
19.610.4
a Recommended value (range).
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Since the aim of this work was to establish a method that could be used 
for the determination of minor Ni isotopes acting as in vivo tracers of Ni 
metabolism, I determined 62Ni added to biological materials of interest for 
metabolic studies, i.e. faeces, urine, blood serum or plasma and red cells 
(Table 3.12), using ID with 61 Ni. The recovery was between 97 and 106%.
Between-run precision was determined on serum and urine samples, 
spiked with 62Ni, that were analysed in different days within three months 
(Table 3.13). Precision was 0.8% for serum samples and 2.4% for urine 
samples and the recovery of the added amounts of 62Ni was 101% for 
serum and 98% for urine. In addition, 18 faecal'samples were analysed in 
replicate in the same day to assess the within-day reproducibility of the 
determination of 60Ni (n=5) and 62Ni (n=13), (Table 3.14). The pooled 
standard deviation obtained for the 60Ni determination was 0.12 pg/g 
(1.3%), for concentrations ranging from 4.6 and 15.1 pg/g. For 62Ni, I 
obtained a pooled standard deviation of 0.19 pg/g (3.7%), for 
concentrations ranging from 0.92 and 10.2 pg/g.
Owing to the need for complete mineralisation of samples, the method 
is limited by high blank values that prevent the determination of low 
concentrations of naturally abundant Ni. In addition, the need to correct 
for blank values introduces an element of inaccuracy, due to variability 
between flasks and individual conditions of mineralisation. Estimated
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Table 3.12 Determination of 62Ni added to biological matrices by means 
of solvent extraction and ID-ICP-MS with 61 Ni
MATRIX
®2Ni
ADDED
M9/L
62Ni
FOUND
pg/L
cv
%
RECOVERY
%
URINE 6.4 6.3 3.1 98
PLASMA 6.4 6.8 3.1 106
RED CELLS 6.4 6.6 3.0 103
FAECES3 0.078 0.076 2.3 97
aM9/g
Table 3.13 Between-day precision observed for serum and urine 
samples spiked with 62Ni.
SERUM URINE
+ 9.6 pg/L 62Ni + 26.5 pg/L 62Ni
RESULT
pg/L
SD
pg/L
RSD% RESULT
pg/L
SD
pg/L
RSD%
1st DAY 9.7 0.15 1.5 26.2 0.18 0.7
2nd DAY 9.7 0.11 1.1 26.7 0.13 0.5
3rd DAY 9.6 0.36 3.8 25.8 0.10 0.4
4th DAY 25.2 0.20 0 .8
MEAN 9.7 0.08 0.8 26.0 0.62 2.4
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Table 3.14 Within run precision of the determination of 60Ni and 62Ni in 
faecal samples using ID-ICP-MS with 61 Ni (pg/g dry weight ± 
standard deviation).
SAMPLE CODE 1st REPLICATE 2nd REPLICATE DIFFERENCE
60 Ni
1 8.71+0.06
2 12.31+0.04
3 15.13 + 0.04
4 6.43 + 0.03
5 4.63 + 0.04
62Ni
1 9.31+0.01
2 7.75 + 0.01
3 2.55 + 0.01
4 0.92 + 0.01
5 8.77 + 0.03
6 6.62 + 0.02
7 2.13 + 0.01
8 3.08 + 0.01
9 8.98 + 0.02
10 9.96 + 0.02
11 1.26 + 0.00
12 3.31+0.01
13 2.85 + 0.01
8.77 + 0.04 -0.06
12.09 + 0.05 0.22
14.90 + 0.07 0.22
6.24 + 0.01 0.19
4.63 + 0.02 0.00
9.28 + 0.06 0.03
7.44 + 0.02 0.31
2.64 + 0.01 -0.09
0.93 + 0.00 -0.01
8.07 + 0.21 0.70
6.39 + 0.02 0.23
2.05 + 0.01 0.08
3.13 + 0.02 -0.05
9.40 + 0.02 -0.42
10.19 + 0.03 -0.23
1.35 + 0.00 -0.09
3.31+0.04 -0.01
3.14 + 0.01 -0.29
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blanks values were about 3 pg/L. However, this is not a limiting factor for 
the determination of the minor isotopes, which are obviously less affected 
by contamination.
Since urine samples contain relatively little organic material, the 
digestion step may be avoided, thus drastically reducing the blank values 
and the time required for analysis. I compared the results obtained for 
eight urine samples at different concentration of 62Ni using the complete 
procedure or omitting the digestion .step (Table 3.15). The results were in 
good agreement and the observed differences were comparable with the 
analytical imprecision of the method.
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Table 3.15 Determination of 62Ni (jjg/L) in urine by means of ID-ICP-MS 
with 61 Ni, after acid digestion and APDC/MIBK extraction or 
direct APDC/MIBK extraction
SAMPLE CODE £CID DIGESTION DIRECT DIFFERENCE
_____________________+ EXTRACTION EXTRACTION (% DIFFERENCE)
BU1 34.4±0.2 34.3±0.2 0.1 (0.4%)
BU2 231.7±0.8 227.5±1.1 4.2(1.8%)
BU3 149.3±0.8 144.7±0.3 4.6 (3.2%)
BU4 2 0 .6±0.2 20.1 ±0.3 0.5 (2.5%)
BU5 10.7±0.1 10.7±0.3 0,1 (0.9%)
BU6 8 .6±0.1 8 .6±0.1 0.1 (0 .6 %)
BU7 10 .0±0.1 10.1 ±0.0 -0.1 ( - 1 .0%)
BU8 9.1 ±0.1 9.2±0.1 -0.1 (-1.1%)
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3.4 CONCLUSIONS
The investigation of separation procedures as a preliminary step to 
remove potential interfering species in ICP-MS proved successful for the 
determination of Ni in HAS and biological materials of human origin. Size- 
exclusion chromatography could be used to a certain extent to determine 
accurately the Ni content in HAS contaminated with Ni. The determination 
of lower Ni concentrations and the analysis of solid samples of interest in 
metabolic studies was obtained by using mineralisation of the samples, 
followed by chelation and solvent extraction. The accuracy and precision 
of the extraction method proved satisfactory for application to the 
investigation of Ni metabolism using 62Ni as a tracer and 61 Ni for ID. 
Further investigations are needed to clarify residual interferences in the 
analysis of tissues, such as the reference materials Pig Kidney and 
Bovine Liver.
To date, this is the first procedure allowing the determination of three or 
more Ni isotopes in a variety of biological materials. Since other metals 
are coextracted, this procedure could be extended to the simultaneous 
analysis of other elements.
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CHAPTER 4
ASSESSMENT OF NI METABOLISM IN MAN 
USING A STABLE ISOTOPE (62Ni) AS A TRACER
4.1 INTRODUCTION
Knowledge of Ni metabolism is mainly derived from animal studies, 
most of them carried out using radioactive isotopes. Most of these 
investigations used extreme exposures, to enhance toxic effects and/or 
simulate work-place exposure. Different animal species were exposed to 
various Ni compounds under different experimental conditions. 
Gastrointestinal absorption was found to be poor (10% in dogs and 3-6% 
in rats). Single or repeated injections of Ni salts (intravenous, 
intraperitoneal or subcutaneous) led to the highest accumulation in the 
kidneys, endocrine glands, lung and liver. Most of the Ni was rapidly 
excreted in urine within 24 h after dosage (65-87%), the rest undergoing a 
much slower elimination (IPCS, 1991).
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Onkelinx and co-workers (1973) proposed a mathematical model of Ni 
metabolism in rats and rabbits based on the observation of Ni 
concentrations in serum and urine for seven days after a single 
intravenous injection of 63NiCl2- The doses were 82 pg/Kg for rats and 
240 pg/Kg in rabbits. In both species they observed a rapid elimination of 
63Ni from blood during the first two days post-injection, whereas 63Ni 
clearance was much slower between the third and seventh day. Rabbits 
eliminated 78% of the Ni dose in urine during the first day. Ni excretion in 
rats during three days post-injection was 78% in urine and 15% in faeces. 
Nickel excretion in bile, measured in two rabbits 5 h after injection, 
averaged 9.2% of the dose. In both species, the experimental results for 
Ni absorption and elimination fitted a two compartment model. The rate 
constants of Ni elimination were calculated as 0.108 and 0.088 I r 1 in rats 
and rabbits, respectively, thus suggesting similar metabolic pathways.
In preliminary experiments intended to compare the results of 
investigations of Ni metabolism using radioactive and stable isotopes, 
Templeton et al. (1994) observed that rats excreted in urine 60 ± 17% of 
the dose of 63Ni, within 80 h of the intravenous injection. An additional 
5.4 ± 1.5% was excreted in faeces. The concentrations observed in serum 
over a period of 72 h fitted a double exponential decay as described by 
Onkelinx et al. (1973).
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Jasim and Tjalve (1986) estimated the intestinal absorption of Ni in 
mice treated with 63Ni to be 1.6%. Nickel was rapidly eliminated in urine 
and 97% of Ni excretion occurred within the first 24 h. The highest tissue 
concentrations of Ni were found in the kidneys, the lungs and the liver 
24 h after oral administration, and in the spinal cord after 72 h.
More recently, Nielsen et al. (1993) reported a study of Ni metabolism 
in mice using a gamma-emitting isotope (57Ni), which allows quantitative 
measurement of whole body retention to be made for as long as 130 h 
after dosage. Mice were given 57Ni either orally or by intraperitoneal 
injection. The doses ingested were between 2.85 and 285 pg/Kg and the 
amounts given by intraperitoneal injection 10-fold lower. Gastrointestinal 
absorption was found to be between 1.7 and 10%. Whole body retention 
decreased rapidly after oral dosage and reached values ranging from 0.02  
to 0.14% of the dose within 45-75 h after oral administration, then 
stabilised. In animals given 57Ni intraperitoneally, whole body retention 
decreased to values ranging from 1 to 2% of the dose within 20-50 h and 
showed no further reduction. The highest Ni concentrations within the 
body were observed in the kidneys, carcass, lungs, testicles, liver and the 
spleen, 8 h after dosage, and in the carcass, kidneys, liver and lungs, after 
20  h.
The findings of these and other studies suggest the absorption,
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distribution and excretion of Ni to be species dependent. Differences in 
the experimental procedures, such as housing, feeding and the 
techniques of collecting and separating the excreta, all contribute to the 
variability of the results. Information obtained from animal studies may be 
of limited use for the understanding of the metabolism of Ni in humans.
Investigations on human volunteers have been restricted to dosing with 
naturally abundant Ni, due to ethical constraints preventing the use of 
long-lived Ni radioisotopes in humans (Spruits and Bongaarts, 1977; 
Cronin et al., 1980; Solomons et al., 1982; Gawkrodger et al., 1986; 
Sunderman et al., 1989).
Spruits and Bongaarts (1977) first reported an investigation of the 
concentrations of Ni in plasma and urine of a healthy, non-allergic 
volunteer, after ingestion of 5 mg of Ni as sulphate. Plasma 
concentrations were measured at 3, 6 , 24, 30 and 48 h. The highest 
concentration (47 pg/L) was found 3 h after dosage, followed by a rapid 
decrease. Nickel concentration in urine remained higher than basal levels 
104 h after dosage.
Cronin et al. (1980) administered doses of 0.6, 1.25 and 2.5 mg of Ni as 
sulphate to three groups of five women, all suffering from hand eczema 
due to Ni hypersensitivity, to investigate whether oral Ni intake caused 
exacerbation of symptoms. Within the next 24 h, blood samples were
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collected using Pt needles and 24 h urine samples were voided into acid- 
washed containers. Serum Ni concentrations had a peak 2.5 h after 
dosage in all groups and ranged from 9 to 16 pg/L, 20 to 58 pg/L and 23 
to 89 pg/L for the three levels of challenge. The amount of Ni excreted 
within 24 h ranged from 48 to 89 pg, from 62 to 253 pg and from 95 to 
206 pg, for the three groups. All patients reported worsening of symptoms 
and the severity of response increased at higher Ni doses.
Solomons et al. (1982) estimated the effects of food and specific food 
components on the bioavailability of Ni for gastrointestinal absorption in 
man. An oral Ni dose (5 mg) was given to volunteers, after an overnight 
fast, and the rise in plasma Ni concentrations was compared with those 
obtained when Ni was given with food, various beverages, phytic acid, 
ascorbic acid, disodium EDTA and sodium iron EDTA. They observed a 
peak of 80 pg/L Ni 3 h after dosage in fasting subjects, but no change in 
Ni concentrations compared to basal levels when Ni was administered 
with food. Cow milk, coffee, tea, orange juice, ascorbic acid and EDTA 
salts also depressed Ni absorption, but Coca-Cola and phytic acid did not.
Gawkrodger and co-workers (1986) carried out a randomised double­
blind crossover study on 26 sensitive subjects using three levels of 
challenge (0.4, 2.5 and 5.6 mg of Ni as sulphate), to clarify the effect of 
oral Ni intake on Ni dermatitis. Nickel concentrations in serum were still
139
about two and a half times higher than basal values 72 h after Ni ingestion 
in patients who had received doses of 2.5 and 5.6 mg of Ni (2.7 ± 0.2 pg/L 
and 2.6 ± 0.7 pg/L, respectively, vs. 1.2 ± 0.3 pg/L). However, clinical 
effects following the ingestion of the Ni dose in comparison with placebo 
were only seen in the group receiving the higher Ni dose. Serum Ni 
concentrations and urinary excretion were also measured in three healthy 
subjects after challenge with 2.5 mg Ni. The rise of serum Ni 
concentrations 3 h after dosage ranged from 30 times to only 5 fold the 
basal concentrations. Urinary excretion, measured in two post-challenge 
24 h urine collections, was also variable and did not correlate with serum 
concentrations. The authors concluded that rather large doses of Ni would 
be necessary to induce adverse effects in Ni-sensitive patients. However, 
the possibility of small amounts of Ni in diet having an effect could not be 
ruled out, because the extent of Ni absorption and excretion varied 
considerably among individuals.
Sunderman et al. (1989) studied Ni absorption and its kinetics in ten 
human volunteers, who ingested doses of 12, 18 and 50 pg/Kg of Ni in 
two separate occasions after an overnight fast (1st experiment) or with 
breakfast (2nd experiment). Baseline values for serum Ni concentration 
and urinary and faecal excretion were obtained from pre-treatment 
samples. Plasma Ni concentration were measured after 1, 3, 7, 10, 24, 48
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and 72 h. Ni excretion was determined in urine and faeces, collected for 
4 days after dosage. Strict precautions to avoid contamination were taken 
during the study. Nickel absorption from the gastrointestinal tract was 
estimated as 27 ± 17% in fasting subjects and 0.7 + 0.4% when Ni was 
ingested with food. Nickel elimination in both faeces and urine after four 
days amounted to 102 ± 8%, in the 1st experiment, and 104 ± 21%, in the 
2nd experiment. The results of this study fitted a two compartment 
mathematical model similar to that developed for rats and rabbits by 
Onkelinx et al. (1973). The rate constants for Ni absorption, transfer and 
elimination did not differ significantly when Ni was administered with water 
or food. The average elimination half time for absorbed Ni was 28 ± 9 h. 
Renal clearance of Ni from the body was estimated as 8.3 + 2.0 
mL/min/1.73 m2, when Ni was ingested with water, and 5.8 ± 4.3 
mL/min/1.73 m2, when Ni was given with food.
According to Santucci et al. (1994) factors controlling Ni metabolism 
within the human body can be altered, thus providing therapeutic 
treatment of Ni dermatitis. These authors reported the administration of 
gradually increasing oral Ni doses to eight Ni sensitive subjects for periods 
between 91 and 178 days. The treatment was well tolerated by all 
subjects who also reported clinical improvement of eczematous lesions 
not involving hands. The improved conditions of the treated patients was
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attributed to reduction of gastrointestinal absorption of Ni and activation of 
renal excretion. Mobilisation of Ni deposits within the body was also 
suggested.
The early studies provided fundamental and invaluable knowledge on 
Ni handling by human beings, and the recent findings of Santucci et al. 
(1994) pose interesting questions. The limitations of these investigations 
arise from the use of naturally abundant Ni and the difficulties of 
separating the information obtained from the Ni dosage and that caused 
by other Ni sources. The dosage used, although safe, was much higher 
than physiological intake, in order to clearly identify the changes in Ni 
concentrations in biological fluids produced by the treatment. Both 
contamination of the samples and variable oral intake of Ni in the diet may 
have contributed to the scatter of results. Specimen contamination by Ni 
was less well controlled in the past. In some of the early studies samples 
were withdrawn using stainless steel needles (Solomons et al., 1982).
Stable Ni isotopes provide a means to overcome these problems. Less 
abundant isotopes, easily identified by their mass difference, can be used 
as tracers. Most confounding factors are thus excluded and lower dosage 
can be used to investigate the system with minimal perturbation. Stable 
isotopes are safe, since there is no radiation risk associated with their use 
and they can be administered even to vulnerable population groups, such
142
as infants and pregnant women. Since stable isotopes do not decay with 
time, the fate of the tracer can be followed for as long as needed and 
samples can be stored to be analysed at a convenient time and place. In 
the past, the applications of stable isotopes to metabolic studies was 
prevented by the need of extensive sample pretreatment and expensive 
instrumentation. Inductively coupled plasma mass spectrometry now 
allows the determination of the isotopic composition of a sample using 
less troublesome procedures than other MS techniques. Stable isotopes 
and ICP-MS have already been used for the investigation of iron 
absorption in women, before and during pregnancy (Whittaker et al., 1989; 
Whittaker et al., 1991; Barrett et al., 1992); Zn absorption in newborns 
(Ziegler et al., 1989; Serfass et al., 1989); Zn kinetics in adults with 
alcoholic liver disease (Lowe et al., 1993); Cu metabolism in healthy 
subjects and patients affected by Wilson's disease (Lyon et al., 1992).
Recently an attempt to investigate Ni metabolism in man using stable 
isotopes and ICP-MS has been reported (Templeton et al., 1994). In this 
study, one subject ingested a dose of 20 pg/Kg of 61 Ni and serum and 
urine concentrations of the isotope were followed for 96 h.
I report here the results of a more complete investigation of the 
absorption, distribution and excretion of Ni in humans, carried out on four 
volunteers, given an oral dose of 62Ni as tracer.
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4.2 EXPERIMENTAL
Subjects: the study was approved by the Research Ethics Committee at 
the Royal Infirmary, Glasgow, and volunteers gave their informed consent 
to the experiment.
The volunteers, two women (B.S., S.M.) and two men (L.W., P.G.), 
aged between 21 and 30 years, were healthy people recruited from the 
hospital staff, who had not suffered from any serious illness during the 
past five years; had regular bowel habit and had no past history of 
hypersensitivity to Ni. All subjects were non-smokers. The only medication 
taken were the contraceptive pill and oral antihistamine (one subject, 
S.M.). Diet was not restricted but guidance was provided about standard 
requirements in terms of fibres and nutrients. One subject (S.M.) was a 
vegetarian.
Organisation o f metabolic experiments: Two separate experiments 
were carried out, each including a woman and a man (B.S. and L.W.; S.M. 
and P.G.). Each experiment lasted 5 days (Monday to Friday). A 24 h 
urine sample and a faecal sample were obtained from each subject the 
week before the experiment.
In each occasion, on Monday morning, a basal blood sample (10 mL)
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was obtained by venepuncture from the two subjects after an overnight 
fast. The blood sample was withdrawn using an intravenous (i.v.) plastic 
cannula (Venflon), which was then left in situ.
Weight and height of each subject were recorded.
The bladder was emptied before drinking a 10 pg/Kg dose of 62Ni (as 
nitrate in HNO3 0.14 M) diluted in approximately 90 mL of water and 
adjusted to pH = 4. Together with the isotope dose, each subject ingested 
two gelatine capsules, each containing 10 radio-opaque barium sulphate 
impregnated polyethylene pellets to act as faecal marker (Cummings et 
al., 1976). The subjects were kept fasting for 2.5 h after the isotope 
ingestion and then allowed to return to their usual eating habits.
Further blood samples (10 mL) were obtained 0.5 h, 1.5 h, 2.0 h, 2.5 h, 
3.0 h, 3.5 h, 4.5 h, 6.0 h (6.5 h in the second experiment) after isotope 
administration via the i.v. cannula. During the following four days a single 
blood sample was taken in the morning, 24 h, 48 h, 72 h and 96 h after 
the isotope ingestion, using standard stainless steel needles and plastic 
syringes.
Urine was voided in separate acid-washed plastic bottles during the 
following time intervals: 0-3 h, 3-6 h, 6-12 h, 12-24 h, 24-48 h, 48-72 h, 
72-96 h, and 96-120 h. The faecal output of each of the four days after the 
isotope ingestion was collected directly into plastic containers.
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Sample collection and storage: Blood samples were collected into 
10 mL acid-washed plastic tubes containing 1.5 mg/mL K2EDTA, free 
from Ni as assessed by GFAAS, and gently mixed several times by 
inversion. Packed cell volume (PCV) was measured on each sample using 
a microhaematocrit centrifuge. The exact volume of each sample was 
recorded and samples were centrifuged at 2500 rpm for 10 min. Plasma 
was separated using acid-washed plastic pipettes, then transferred into an 
acid-washed plastic tube and stored at -20°C. Red cells were washed 
three times with saline solution (0.9% NaCI, 'Aristar' grade, 99.99%), then 
diluted to the original volume of the blood sample with de-ionised water 
and stored at -20°C.
Urine samples were weighed and urine volumes determined multiplying 
by an average urine density of 1.02 g/mL. After thoroughly mixing, an 
aliquot of 100 mL was withdrawn and stored at -20°C.
Faeces were weighed and stored at 4°C. The number of radio-opaque 
pellets excreted in each sample was counted by X-ray visualisation using 
a Phillips BV 21 S Image Intensifier. Pellets were counted twice with the 
container in two different planes. Each stool was homogenised after 
addition of a known amount of water, depending on the size and 
consistency of the sample, using a Silverson Model L2R homogeniser. An 
aliquot of 50 mL was freeze-dried for 24 h or until constant weight was
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reached. The lyophilised samples were then ground in a mortar to a fine 
powder and stored in plastic containers at room temperature.
Nickel analysis: Plasma, urine, red cells and faecal samples were 
analysed by ICP-MS, after isotopic dilution with 61 Ni, acid-digestion and 
extraction with APDC/MIBK, as described in Chapter 3.
Since impurities contained in H2SO4 made the highest contribution to 
blank values, the mixture for acid digestion was made up with 3.5 parts of 
HNO3 , 1 part of HCIO4 and only 0.5 part of H2SO4 .
Urine samples (10 mL) were directly extracted with APDC/MIBK without 
digestion. Before extraction, samples were thawed, acidified to a final 
concentration of 1% HNO3 and centrifuged at 2500 rpm to remove any 
precipitate.
Two aliquots of 0.1-0.2 g of each freeze-dried faecal sample were 
weighed directly into 50 mL conical glass flasks, diluted with 2.5 mL water 
and digested with 7.5 mL of acid mixture. One portion was used to 
determine the concentration of 62Ni, given as tracer, and the other to 
measure the amount of 60Ni, from which the amount of naturally abundant 
Ni, excreted in faeces as a result of dietary intake, could be calculated.
Each set of samples, for a given subject and matrix (plasma, red cells, 
urine and faeces), was analysed within the same day to reduce variability.
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Control samples were prepared from pooled serum and urine spiked 
with known amounts of 62Ni and analysed together with the plasma and 
urine samples obtained from the subjects of the experiment to check the 
accuracy of the results.
Concentration of spiking solutions: Three solutions of 61 Ni were 
prepared at 0.1, 0.5 and 5 mg/L and their concentration confirmed by 
means of ICP-MS using inverse calibration (see Chapter 3).
Additional analysis: Serum and urine creatinine was determined by the 
Jaffe' method, using commercial kits. Creatinine clearance, normalised 
according to body surface area (Burtis and Ashwood, 1994), was 
calculated with the following formula:
Volume of plasma cleared (mL)
Creatinine clearance = ----------------------------------------------------
time (min) x standard surface area
i.e.
U-Crea (mmol/L) x U-Flow (mL/min) x1.73
Creatinine clearance = --------------------------------------------------------------
P-Crea (mmol/L) x BSA (m2)
where U-Crea indicates urinary creatinine; U-Flow, the volume of urine 
(mL) which passes through the kidney in one minute; P-Crea, plasma
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creatinine and BSA, the Body Surface Area, as obtained from standard 
nomograms (Burtis and Ashwood, 1994), using height and weight records.
4.3 RESULTS AND DISCUSSION
Details on each subject taking part in the study, including sex, age, 
weight, height, body surface area, average packed cell volume (PCV%) 
and total amount of 62Ni received, are given in Table 4.1.
The observed daily output in faeces of radio-opaque pellets, dietary Ni 
and 62Ni are reported in Tables 4.2, 4.3, 4.4 and 4.5, separately for each 
volunteer.
In all cases, the number of pellets given (20) was completely recovered 
in faeces within five days after ingestion, although patterns of faecal 
excretion differed. One of the volunteer, consuming a vegetarian diet, 
excreted 18 of the 20 pellets within 24 h, whereas the others required a 
longer time.
Radio-opaque plastic pellets were suggested by Cummings et al. 
(1976) as an ideal marker to estimate the transit time of digesta through 
the human gut. These pellets behave as closely as possible to natural 
dietary residues, because they do not interact with the gastrointestinal
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Table 4.1 General details on volunteers taking part in the 62Ni study 
Subject B.S. L.W. S.M. P.G.
SEX F M F M
AGE, yrs 30 28 21 30
WEIGHT, Kg 66.2 77.5 59.2 86.5
HEIGHT, cm 162 186 169 179
BODY SURFACE AREA, m2 1.70 2.02 1.68 2.06
PCV% 40 45 38 48
TOTAL 62Ni DOSE, pg 670 760 571 879
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system and their specific gravity, ranging from 1.3 to 1.6, is close to that of 
faeces. There are no risks associated with their use and their detection is 
simple and safe. The average transit time (ATT) of digesta in subjects 
given a single dose of pellets is calculated as:
ATT = I  (xj tj)/E xj
(where xj is the number of pellets excreted in each day and tj the time (h) 
elapsed since marker ingestion). In this study I observed ATT values of 
55.2, 39.6, 26.4 and 68.4 h, for B.S., L.W., S.M. and P.G., respectively. 
This corresponds to an average value of 47.4 h (SD 18.3; SEM: 9.1) and, 
if I exclude the vegetarian subject, 54.4 h (SD: 14.4; SEM: 8.3). In a group 
of 6 healthy young men eating a free diet, Cummings et al. (1976) 
observed an average ATT of 55.2 h (range 16.8-96), which decreased to
38.4 h when additional fibre was included in the diet (n=5).
In all volunteers, the pattern of excretion of the faecal marker closely 
followed that of 62Ni (Figs. 4.1 - 4.4). Therefore, I am confident that the 
recovery of 62Ni not absorbed from the intestine was also complete.
The average concentration of dietary Ni observed in faeces of all 
subjects, (except the basal sample of subject S.M., which was reckoned 
incomplete), was 2.2 ± 1.1 pg/g wet weight (w.w., n= 19; range: 0.9-5.0) 
and 7.9 ± 3.3 pg/g dry weight (d.w., n=19; range: 3.5-15). The average 
percentage of dry mass was 27.8 ± 4.4% (n=19, range 20.5-39.2).
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Fig. 4.1 Faecal excretion of 62Ni (circles) and radio-opaque pellets 
(squares) after dosage (B.S.).
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Fig. 4.2 Faecal excretion of 62Ni (circles) and radio-opaque pellets 
(squares) after dosage (L.W.)
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Fig. 4.3
Fig. 4.4
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Faecal excretion of 62Ni (circles) and radio-opaque pellets 
(squares) after dosage (S.M.).
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Faecal excretion of 62Ni (circles) and radio-opaque pellets 
(squares) after dosage (P.G.)
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Daily faecal excretion of naturally occurring Ni averaged 
255 ± 92 M9/day, (n=18; range: 74-388; 1 outlier excluded). Average 
individual Ni excretion, computed from the mean value of daily Ni 
excretion over five days, for the four subjects, was 288 ± 60 pg/day 
(n=4, range 199-326). Nodiya (1972) observed an average excretion of Ni 
of 258 ± 23 pg/day (range 219-278) in three-day faecal collections from 
ten Russian students consuming a school diet. Horak and Sunderman 
(1973) measured Ni in three-day collections of faeces from ten North 
American adults consuming a free diet. They reported an average 
Ni faecal concentration of 3.3 ± 0.8 pg/g w.w. (range 2.1-4.4); 
14.2 ± 2.7 pg/g d.w. (range 10.8-18.7) and daily faecal excretion 
258 ± 1 2 6  pg/day (range 80-540). The average concentration of Ni 
determined by Sunderman and co-workers (1989) in two-day faecal 
collections from ten subjects in the USA was 1.5 ± 0.5 pg/g w.w. 
(range: 1.0-2.2) and average daily faecal excretion was 158 ± 75 pg/day 
(range: 69-289).
The average daily excretion of Ni in faeces observed in this study is in 
agreement with previous reports and consistent with the estimate of 
dietary Ni intakes in the UK. Smart and Sherlock (1987) reported that 
people in the U.K. may ingest between 140 and 150 pg/day of Ni in food, 
with an additional 100 pg/day released from cooking utensils.
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The concentration of naturally abundant Ni in faeces was quite high and 
rather variable on a day-to-day basis (Tables 4.2-4.5). This variability may 
have affected the estimate of the gastrointestinal absorption of Ni in 
experiments where volunteers ingested naturally abundant Ni. The use of 
a tracer should eliminate these problems. However, due to the high 
content of total Ni in human faeces, the amount of 62Ni naturally present is 
not negligible and could still affect results, although to a minor extent. 
Therefore, I calculated the amount of 62Ni from the diet as a percentage 
(3.66%) of the content of naturally abundant Ni, measured in the faecal 
samples using the isotope 60Ni, and corrected the data of 62Ni excretion 
accordingly (Tables 4.2-4.5). The fraction of 62Ni from the diet ranged 
between 5.1% and 13.2% of the total amount of tracer excreted in faeces.
Faecal excretion of the tracer in the four volunteers averaged 
66.9 ± 4.9% (range 59.9-71.3) of the dose and the absorbed fraction was 
calculated to be 33.1 ± 4.9%.
The plasma concentrations of 62Ni observed in each of the four 
volunteers at definite time intervals (Table 4.6) are plotted against time in 
Fig. 4.5. Although large individual variability has been reported in earlier 
studies, the set of results observed in this group of subjects at each time 
were in close agreement (Table 4.6). Plasma 62Ni had a peak between
1.5 and 2.5 h, at concentration ranging between 16.7 and 21.3 pg/L.
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Table 4.6 Plasma 62Ni concentrations (pg/L) at definite times after 
dosage in four volunteers. Mean and standard deviation of 
all of the concentrations observed for each time are also 
reported.
Time
(hrs)
BS LW SM PG Mean SD
0 0 0 0 0 0
0.5 15.0 6.6 4.2 4.2 7.5 5.1
1.5 18.0 15.3 19.2 20.4 18.2 2.2
2 . 0 16.3 16.7 19.7 21.3 18.5 2.4
2.5 16.3 16.4 20.8 - 17.8 2.6
3.0 15.1 16.3 20.1 18.4 17.5 2.2
3.5 13.7 15.8 19.7 16.6 16.5 2.5
4.5 11.7 12.8 17.3 14.3 14.0 2.4
6 . 0 10.2 10.5 10.4 0.1
6.5 12.4 11.2 1 1 . 8 0.6
24 4.1 3.5 3.8 3.1 3.6 0.4
48 2.7 1.6 1.6 2.5 2 .1 0.6
72 1.9 1.0 0.8 1.6 1.3 0.5
96 _ 0.7 0.5 1.0 0.7 0.3
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Other studies reported the highest plasma concentration to occur at 2.5h 
or 3h (Spruits and Bongaarts, 1977; Cronin et al., 1980; Solomons et al., 
1982; Gawkrodger et al., 1986; Sunderman et al., 1989). However, only 
Solomons et al. (1982) investigated serum Ni concentrations between 0 
and 2.5 h. In a recent study, Templeton et al. (1994) also observed the 
peak of serum Ni concentrations at 2.0 h in a volunteer who ingested a 
dose of 61 Ni and had blood samples at 30 min intervals for 3 h after 
dosage. Clearance of 62Ni was rapid and 24 h after ingestion plasma 
concentrations had dropped to between 3.1 and 4.1 pg/L. However, 62Ni 
was still detectable in plasma 96 h after dosage, at concentrations ranging 
from 0.5 and 1 pg/L, comparable with values expected for plasma Ni in 
unexposed subjects.
The effect of contamination with naturally abundant Ni from the needles 
and other sources on the results of investigations of Ni absorption in blood 
is shown in Fig. 4.6. Total Ni, determined in the plasma samples by 
GFAAS, was generally higher than the concentration of 62Ni, determined 
by ICP-MS. All results are transformed in pmol/L, as data expressed on a 
mass basis are biased by the difference in mass between the single 
isotope (mass 62) and total Ni, which is a mixture of five isotopes (average 
mass 58.71). To compare the results of determinations of 62Ni and total Ni 
in plasma of rats, Templeton et al. (1994) adopted stringent
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contamination control, including flushing the stainless steel needles used 
for blood sampling with 3 mL of blood before sampling.
Analysis of the results obtained for plasma 62Ni concentrations, by 
means of a commercial pharmacokinetics programme (SIFAR, Milano, 
Italy), suggested that the log-concentration vs. time plot was best fitted by 
a function including three-exponential components. The values derived for 
the area under the curve (AUC), elimination half-time and 62Ni clearance 
using this mathematical approach, are reported in Table 4.7 for the four 
volunteers. The overall inter-individual variation of the absorption and 
clearance of 62Ni from the blood, evaluated from the dispersion of 
the AUC values, was only 10%. Average elimination half-time was
25.5 ± 4.4 h and Ni clearance from plasma was 10.4 ±2.1 mL/min, as 
compared with 28 ± 9 h and 8.3 ± 2.0 mL/min observed by Sunderman et 
al. (1989).
The concentrations of Ni in serum and in whole blood have been 
reported to be similar in unexposed subjects (Hopfer et al., 1985). In vitro 
studies of cellular uptake of Ni suggest that high concentrations of albumin 
and aminoacids may prevent Ni transport across the cellular membrane of 
erythrocytes (Niebor et al., 1984, 1988). I have attempted to assess the 
distribution of Ni between red cells and plasma in vivo. The concentration 
of 62Ni was determined in red cell samples taken from two
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Table 4.7 Information derived from mathematical fitting of the plot 
log-plasma 62Ni concentrations vs. time.
Peak Cone. Peak time AUC* Elimination Total 62Ni
pg/L h hpg/L half-time clearance
h ml/min
B.S. 18.0 1.5 426 28.8 7.4
L.W. 16.7 2.0 340 24.0 12.3
S.M. 20.8 2.5 366 20.0 10.8
P.G. 21.3 2.0 408 29.2 11.1
MEAN 19.2 2.0 385 25.5 10.4
SD 2.2 0.4 39 4.4 2.1
CV% 11.5 20.4 10 17 2.0
MIN 16.7 1.5 340 20.0 7.4
MAX 21.3 2.5 426 29.2 12.3
*Area Under the Curve: log-62Ni concentration vs time
165
of the volunteers (S.M. and P.G.) after ingestion of the isotope. In both 
cases, the concentrations of 62Ni in red cells were much lower than that in 
the respective plasma samples. Unfortunately, the concentrations in the 
haemolysates presented to the ICP-MS were too low for acceptable 
analytical reliability. Although we require more precise analyses, the 
pattern of 62Ni concentrations in red cells obtained for one subject are 
presented in Table 4.8. The uptake of 62Ni by erythrocytes occurs slowly 
and reaches a peak of around 3.0 pg/L at about 48 and 72 h after 
ingestion.
Creatinine clearance and intra-individual variability for all subjects were 
within the expected reference range for healthy subjects (94.2 ± 12.7 
mL/min/1.73 m2; Gowan and Fraser, 1988), thus reflecting normal renal 
function and completeness of urinary collections. A lower day-to-day 
variability was observed for the vegetarian subject (S.M.), due to the lack 
of dietary creatinine intake. Individual average daily urinary volume ranged 
from 1015 to 1755 mL and average urinary flow was between 0.71 and 
1.22 mL/min. The values observed for urinary volume, flow, creatinine 
excretion, serum creatinine and creatinine clearance for the four subjects 
are reported in Appendix.
Urinary concentrations and daily excretion of 62Ni for all subjects are 
reported in Table 4.9. Daily and cumulative urinary excretion from all
166
Table 4.8 Concentrations of 62Ni measured in erythrocytes of one 
subject (S.M.) at definite time intervals after dosage.
Time (h) 62Ni concentration
____________________ (pg/L erythrocytes)
0 0
0.5 0.3
1.5 0.3
2 0.4
2.5 0.7
3 0.6
3.5 0.6
4.5 0.8
6.5 0.9
24 2.5
48 2.9
72 2.7
96 2.1
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subjects are plotted against time in Figs. 4.7 and 4.8 as percentage of the 
absorbed dose. The results show a large inter-individual variability in Ni 
excretion, only partially explained by the differences in urinary volumes 
and flows. Five days after ingestion, the elimination of Ni was not 
complete in any of the subjects. The concentrations of 62Ni in urine 
collected on the fifth day (2.1 to 9.2 pg/L) was still higher than the 
concentrations found in urine of unexposed subjects. The percentage 
of the absorbed dose excreted in urine averaged 65.2 ± 13.4% 
(range 50.4-82.0).
The results of this metabolic study are summarised in Table 4.10, which 
gives the absorbed, excreted and retained fractions of the dose of 62Ni 
found for each subject. The 62Ni dose was relatively small and 
comparable with the amount of Ni that can be ingested with diets rich in 
certain types of food such as dark chocolate, nuts and soy products. This 
is the lowest amount used up to now in investigations of Ni metabolism in 
humans. Doses of 0.4 and 0.6 mg Ni have been administered during 
studies of clinical responses of Ni-sensitive patients to oral Ni intake. In 
this study, the gastrointestinal absorption of Ni was fairly similar in three of 
the volunteers, but was higher (+25%) for the fourth subject (S.M.). This 
subject is a young vegetarian woman, who may have inadequate iron 
intake. It has been reported that Ni absorption is increased in
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Fig. 4.7 Urinary excretion of 62Ni after dosage as a percentage of the 
absorbed dose in the four subjects.
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Fig. 4.8 Cumulative urinary excretion of 62Ni after dosage as a 
percentage of the absorbed dose in the four subjects.
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Table 4.10 Absorption, excretion and retention of the 62Ni dose in each of 
the four subjects, expressed as absolute amount, percentage of 
the dose and percentage of the absorbed dose.
Absolute amount, pg
B.S. L.W. S.M. P.G. Mean SD
Total ®2Ni dose, pg 670 760 571 879
Total faecal excretion, pg 478 514 342 604
Absorbed dose, pg 192 246 229 275
Total urinary excretion, pg 97 169 188 166
Retained amount, pg 95 77 41 109
% of dose
Total ®2Ni dose 100.0 100.0 100.0 100.0
Total faecal excretion, % 71.3 67.6 59.9 68.7 66.9 4.9
Absorbed dose, % 28.7 32.4 40.1 31.3 33.1 4.9
Total urinary excretion, % 14.5 22.3 32.9 18.9 22.1 7.8
Retained amount, % 14.2 10.1 7.2 12.4 11.0 3.0
% of absorbed dose
Absorbed dose, % 100.0 100.0 100.0 100.0
Total urinary excretion, % 50.4 68.5 82.0 59.8 65.2 13.4
Retained amount, % 49.6 31.5 18.0 40.2 34.8 13.4
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iron-deficient rats (Tallkvist et al., 1994). This suggests that iron status 
should be assessed in volunteers chosen for studies of Ni absorption.
The percentage of the absorbed dose excreted in urine showed a 
wider variability from subject to subject, that can be partially explained in 
terms of total amount of urine passed. The percentage of dose retained in 
the body at the end of the experiment ranged from 7.2 to 14.2% of the 
amount of 62Ni given, corresponding to 18 and 49.6% of the absorbed 
dose.
Biliary excretion has been suggested as a route of Ni elimination on the 
basis of evidence of biliary excretion in rats and rabbits (Onkelinx et al., 
1973) and the measurement of Ni in human bile specimens (Rezuke et al., 
1987). However, Sunderman et al. (1989) did not find evidence of 
enterohepatic circulation of Ni, such as secondary peaks of plasma and 
urinary concentrations, nor did I. In this study, for the first time, I was able 
to assess the pattern of faecal excretion of Ni, as the tracer could be 
distinguished from naturally occurring Ni ingested with food. The 
elimination of 62Ni in faeces showed a constant decline and followed the 
same pattern observed for the faecal marker (Figs. 4.1-4.5). This confirms 
that biliary excretion of Ni is absent or very small in humans.
A comparison of the estimates of Ni absorption, excretion and retention 
obtained in the two complete studies on humans is reported in Table 4.11.
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Table 4.11 Estimates of Ni absorption, excretion and retention, as 
percentage of the dose, using naturally occurring Ni or a 
stable isotope (62Ni).
Sunderman et al. 
1989 
Ni 
4 days
This study 
1993 
62Ni 
5 days
Mean SD Mean SD
Faecal excretion, % 76 19 66.9 4.9
Urinary excretion, % 26* 14* 22.1 7.8
Total excretion, % 102 8 89.0 3.1
Absorbed fraction, % 27 17 33.1 4.9
Retained fraction, % 0 11.0 3.0
* derived from figure
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For ail parameters, the results of this experiment show a much lower 
inter-individual variability than that observed by Sunderman et al.(1989), 
dosing with naturally occurring Ni. There is a difference in the estimate of 
total Ni excretion between the two investigations, although similar results 
are obtained for the evaluation of gastrointestinal absorption. The average 
faecal excretion I found was about 9% lower than that measured by 
Sunderman et al. and the urinary excretion was 4% lower. Whereas 
Sunderman et al. concluded that Ni was completely eliminated from the 
body within 4 days, I found that a considerable fraction of the absorbed 
dose (34.8% ± 13.4) was still retained five days after ingestion. These 
results are confirmed by recent observations of Templeton et al. (1994), 
who administered an oral dose of 61 Ni to one volunteer and reported a 
cumulative urinary excretion of 27% and still increasing 96 h after the 
isotope ingestion.
4.4 CONCLUSIONS
In conclusion, the use of a stable isotope for the investigation of Ni 
metabolism in humans had several advantages, including the possibility of 
using more physiological dosages. I needed less stringent precautions
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against contamination and the fate of the tracer could be followed for a 
longer period at lower concentrations. The results of this study have 
highlighted that Ni excretion and inter-individual variability may have been 
overestimated and complete elimination of Ni from the body may take 
longer than previously reported.
Estimates of long-term retention of the absorbed Ni fraction should be 
considered with caution, as the non-exchangeable or slowly exchangeable 
fractions can apparently be increased by any losses of Ni due to 
incomplete faecal and urine collections. However, in this study, the faecal 
marker given with the Ni dose was completely recovered from all subjects 
and the retention of Ni was also confirmed by the plasma and urine 
concentrations. These results are also consistent with recent reports of 
long-term Ni retention in mice, that were given amounts of Ni comparable 
with human dietary intake, but using a radioactive gamma emitting Ni 
isotope (Nielsen et al., 1993).
The investigation of the processes involved in the slow exchange of Ni 
in tissue will require further study. Preliminary results on the kinetics of Ni 
uptake from erythrocytes in vivo have been presented. The speciation of 
Ni in plasma, that could also be carried out using the stable isotope 
technique, could provide further insight.
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CHAPTER 5
CONCLUSIONS
The aim of this work was to gather information as to risk of clinical 
toxicity of Ni from inadvertent exposure during various medical treatments. 
This required a survey of sources of exposure and the determination of Ni 
concentration in body fluids of potentially exposed patients.
Monitoring clinical exposure to Ni is hampered by its low concentrations 
in body fluids, limited sensitivity of analytical techniques and the high risk 
of contamination. Analytical procedures need to be carefully validated to 
ensure that reliable results are obtained to allow meaningful conclusions.
I assessed the performances of analytical methods, based on GFAAS 
with deuterium background correction and ICP-MS with stable isotope 
dilution, for the determination of total Ni and selected Ni isotopes in 
biological samples. The GFAAS method proved accurate and reliable for 
the study of clinical exposure to Ni, although not sensitive enough for the 
determination of the lower Ni concentrations in serum of unexposed 
people. Although in principle, ICP-MS could provide lower detection limits,
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the analysis of biological samples by this technique required acid 
digestion and solvent extraction steps, which had reagent blank levels of 
about 3 pg/L, and prevented the exploitation of the full potential of this 
technique. I intend to carry out further work to improve the present 
ICP-MS method, to allow the determination of lower concentrations and 
reduce the time required for analysis. This will include the use of 
microwave pressure vessel digestion and on-line separation methods, 
based on chelation chromatography with immobilised iminodiacetate.
I have shown that the Ni content in human albumin solutions from 
recent production has dramatically decreased. Similarly, the 
concentrations of Ni I measured in serum of a group of haemodialysed 
patients are lower than previously described, although still high in 
comparison with the most recent estimates of serum Ni concentrations for 
unexposed subjects (0.14 ± 0.09 pg/L).
These results indicate that the risk of Ni toxicity during clinical treatment 
is minimal. However, the Ni concentrations observed in human albumin 
solutions are still higher than normal blood serum concentrations and 
could trigger allergic reactions in hypersensitive subjects. People with 
healthy kidneys can rapidly eliminate in urine any excess of Ni 
inadvertently administrated to them, but the risk of Ni retention and 
accumulation in tissue of patients with impaired renal function remains a
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possibility. Evidence for this could be obtained by comparing the Ni 
concentrations in autopsy tissues from patients who suffered from chronic 
renal failure and those suffering accidental deaths. Periodical surveys of 
Ni concentrations in human albumin solutions and other products for i.v. 
injection are desirable and could be carried out using the methods 
described here.
I have shown that hypernickelaemia still occurs in patients maintained 
on haemodialysis, although the concentrations of Ni in dialysis fluids is 
now less than 0.5 pg/L. Olerud et al. (1984) demonstrated that Ni can be 
transferred into blood against a concentration gradient due to high affinity 
of Ni for plasma proteins, such as albumin. However, in this work I did not 
obtain conclusive evidence of Ni uptake during the dialysis cycle. The 
observation, already reported in literature, that serum Ni concentrations do 
not correlate with the length of dialysis treatment was also confirmed.
In addition to Ni uptake in blood from contaminated dialysis fluids, 
inefficient excretion of Ni present in diet could contribute to 
hypernickelaemia. Dietary intake of Ni is rather high and variable, ranging 
from 100 to 900 pg/day, with a gastrointestinal absorption estimated 
between 1 and 5%. Nickel in blood is strongly bound to proteins and its 
excretion in urine involves the formation of a ternary complex of Ni, 
albumin and L-histidine (Glennon and Sarkar 1982). This mechanism may
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not be efficient during dialysis and removal of Ni from the body may be 
incomplete. This possibility could now be investigated using the method I 
have developed to follow the decline of plasma concentration of a stable 
Ni isotope administered by i.v. injection to patients on haemodialysis. The 
results could then be compared with the information I obtained on healthy 
people.
Most of the studies of Ni absorption, distribution and excretion were 
carried out on animals using high Ni doses to enhance toxic responses. 
The findings of such investigations provide little information on the 
consequences of mild exposure, such as that experienced by some 
patients following some medical treatments. The few studies carried out 
on humans suffered from methodological limitations, as ethical constraints 
prevented the use of radioactive Ni isotopes as tracers.
I reported here the results of the first complete investigation of Ni 
metabolism in humans, carried out using stable isotopes. As a result of 
the exclusion of confounding factors, such as sample contamination and 
variable dietary intake, Ni absorption and excretion could be accurately 
evaluated and inter-individual variability assessed. The most important 
conclusion of this study was that, even in healthy subjects, complete 
elimination of Ni requires longer than previously reported. The processes 
involving slow-exchange of Ni and the mechanisms of Ni excretion need
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to be investigated and further work will be carried out using the stable 
isotope technique to obtain additional information on the distribution of 
labelled Ni among plasma protein fractions and in red cells as a function 
of time. The speciation of Ni in urine could also help clarifying the 
mechanism of Ni excretion.
Besides providing more accurate information on Ni metabolism in 
healthy subjects, the stable isotope technique could be applied to 
investigate a number of issues, related to clinical and environmental 
exposure to Ni, such as the increased gastrointestinal absorption of Ni in 
iron-deficient subjects and patients undergoing therapy with chelating 
agents. Such investigations were previously restricted to animal studies 
(Tallkvist et al., 1994; Tallkvist and Tjalve, 1994; Nielsen and Andersen, 
1994).
Differences in gastrointestinal absorption of Ni among hypersensitive 
subjects have been suggested as an explanation for contradictory clinical 
responses to oral doses of Ni sulphate. Both a low Ni dietary intake and 
prolonged treatment with oral Ni have been reported to be beneficial to 
patients suffering from Ni contact dermatitis. In a recent report, Santucci et 
al. (1994) claimed that therapeutic administration of oral Ni, in doses 
ranging from 0.6 to 2 mg Ni for periods between 3 and 6 months, reduced 
gastrointestinal Ni absorption, activated renal excretion and promoted
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mobilisation of Ni deposits. The stable isotope technique could be used to 
confirm these findings and clarify the scientific basis of the therapy.
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Table A2 Serum creatinine values (pmol/L) measured in samples from
the 4 volunteers taken at the defined times.
Time (h) BS LW SM PG
0 82 102 85 111
0.5 87 98 85 109
1.5 83 100 90 111
2 82 97 84 111
2.5 84 94 80 114
6 82 103
6.5 61 120
24 82 97 87 114
48 79 95 80 116
72 81 96 79 112
96 79 97 87 97
MEAN 82.1 97.9 81.8 111.5
SD 2.3 2.9 8.1 6.0
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